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Abstract 
 
Objectives: 
The main objective of this study is to conduct a full analytical profile for Cat's claw 
and Devil's claw, two herbal medications containing Isomitraphylline and 
Harpagoside respectively. The study included the long term stability of the capsules 
and standards, development and validation of stability indicating HPLC methods for 
analysis of both drugs and studying of their kinetics.  
The study also included determination of elements present, studying the 
microbiological stability for both drugs and running toxicity studies in mice. 
Method 
Stability studies: 
Both herbal drugs were stored under different simulated climatic conditions: Climatic 
chamber No. 1 (25°C ± 1°C, humidity: 75%); Climatic chamber No. 2 (30°C ± 1°C, 
humidity: 75%) and Climatic chamber No. 3 (35°C ± 1°C, humidity 75%).  
HPLC methods were adopted to follow isomitraphylline and harpagoside standards 
and good separation for active ingredients in Cat's claw and Devil's claw capsules 
from other excepients.The optimum separation was obtained using C18 Hypersil 
column, acetonitile and 10mM phosphate buffer pH 6.6 as mobile phase, and 245nm 
as wavelength of detection for Cat's claw . C18 Hypersil column,40 volumes of water 
and 60 volumes of methanol as mobile phase and 278nm wave length were used for 
the detection for Devil's claw. Elemental analysis was done using atomic absorption 
spectrophotometer. Microbiological analysis was carried out using the standard 
protocol for the total viable count. 
Toxicity studies: 
The studies were carried out using Swiss albino mice aged 6-7 weeks, for acute, 
subacute and chronic toxicity studies. 
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Results 
Stability studies: 
Physical examination on the Cat’s claw powder and shell over the period of 24 
months showed change in the capsule contents under CH3 storage condition as it 
became dark brown while under CH2 and CH3 storage conditions the capsule 
contents became like hard cylindrical lumps.  
The developed HPLC methods used for both drugs were validated and found to be 
accurate, sensitive and precise.  
The reaction rate constant (K), the half life (t1/2) and the rate of decomposition were 
calculated for Cat's claw and Devil's claw.  
Current studies on the elemental composition of Cat’s claw and Devil's claw capsules 
confirmed absence of toxic heavy metals. 
Microbiological studies on Cat’s claw and Devil's claw capsules revealed no 
significant changes in total viable aerobic count of bacteria and fungi.  
Toxicity studies: 
Hematological studies for Cat's claw revealed a significant reduction in WBC levels 
upon acute treatment of male and female mice as compared to the control, while for 
Devil's claw no significant differences were noticed between treated and control 
groups. Biochemical studies for Cat's claw showed significant rise in the levels of 
AST and ALT in acute and subacute treated mice, but for Devil's claw remained 
normal. 
Hematological studies for Cat's claw on the chronically treated male and female mice 
revealed no differences as compared to the control, except for a mild increase in 
platelet count. The results for Devil's claw revealed no significant differences 
compared to control. Biochemical studies for Cat's claw revealed a non-significant 
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increase in AST and ALT in the male group, while no changes were observed for 
Devil's claw. Histopathological modifications (heart, liver, kidneys and lungs) were 
not observed in mice treated with Cat's claw and Devil's claw. 
Conclusion 
From the current study both drugs were found to be stable under the following storage 
conditions: 25°C / 75% RH, 30°C / 75% RH, 35°C / 75% RH.  
It can be concluded that Cat’s claw capsules should be stored under the recommended 
storage conditions.  
Toxicity studies revealed that Cat’s claw and Devil's claw acute treatment were 
devoid of any clastogenic potentials. Hematological and biochemical studies revealed 
no drastic changes indicating that Cat’s claw and Devil's claw possess non-significant 
toxicity during chronic toxicity. Chronic treatment with Cat’s claw and Devil's claw 
induced no clastogenic or cytotoxic effect.  
The low toxicity of Cat's claw and Devil's claw as evidenced by key hepatic enzymes 
stability and organ integrity suggests a wide margin of safety for therapeutic doses of 
Cat's claw and Devil's claw. 
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  ﺺ اﻟﺒﺤﺚﻠﻣﺴﺘﺨ
  
  -:اﻷهﺪاف 
ﻟﻤﺴﺘﺤѧﻀﺮي ﻣﺨﻠѧﺐ اﻟﻘѧﻂ وﻣﺨﻠѧﺐ  ﱢﺷѧﻬﺮا 42اﺳѧﺔ ﺛﺒﺎﺗﻴѧﺔ ﻃﻮﻳﻠѧﺔ اﻷﺟѧﻞ ﻟﻤѧﺪة درﺗѧﺘﻠﺨﺺ أهѧﺪاف هѧﺬﻩ اﻟﺮﺳѧﺎﻟﺔ ﻓѧﻲ 
اﻟﺘﺤﻘﻖ ﻣﻦ ﺻﺤﺔ ﻃﺮﻳﻘѧﺔ وآﺬﻟﻚ .ﻮﺳﺎﻳﺪ ﻗﺎ اﻳﺰوﻣﺘﺮاﻓﻠﻴﻦ وهﺎرﺑﺎﻤاﻟﺸﻴﻄﺎن ﻓﻲ هﻴﺌﺔ آﺒﺴﻮﻻت وﻟﻠﻤﺎدﺗﻴﻦ اﻟﻔﺎﻋﻠﺘﻴﻦ ﺑﻬ 
دراﺳѧﺔ ﺣﺮآﻴѧﺔ اﻟﻤﺴﺘﺤѧﻀﺮﻳﻦ وﺣѧﺴﺎب و . وﺟѧﻮد اﻟﻤѧﻮاد اﻟﻤѧﻀﺎﻓﺔ ﻓѧﻲ  اﻟﺘﺤﻠﻴﻞ اﻟﻜﺮوﻣﺎﺗﻮﻏﺮاﻓﻲ ﻟﻜﻼ اﻟﻤﺴﺘﺤﻀﺮﻳﻦ 
 اﻟﻤﻌﺪﻧﻴѧѧѧﺔ اﻟﻤﻮﺟѧѧѧﻮدة ﺤﺪﻳѧѧѧﺪ اﻟﻌﻨﺎﺻѧѧѧﺮ آﻤѧѧѧﺎ ﺗﻨﺎوﻟѧѧѧﺖ اﻟﺪراﺳѧѧѧﺔ ﺗ  .ﻟﺘﻔﺎﻋѧѧѧﻞ ، ﻧѧѧѧﺼﻒ اﻟﻌﻤѧѧѧﺮ وﻃﺎﻗѧѧѧﺔ اﻟﺘﻜѧѧѧﺴﻴﺮ ﺛﺎﺑѧѧѧﺖ ا
اﺟѧѧѧﺮاء دراﺳѧѧѧﺔ ﺳѧѧѧﻤﻴﺔ ﻟﻜѧѧѧﻼ و ﺗѧѧѧﻢ .اﻟﺜﺒﺎﺗﻴѧѧѧﺔ اﻟﻤﺎﻳﻜﺮوﺑﻴﻮﻟﻮﺟﻴѧѧѧﺔ ﻟﻜѧѧѧﻼ اﻟﻤﺴﺘﺤѧѧѧﻀﺮﻳﻦ دراﺳѧѧѧﺔ و.ﻟﻤﺴﺘﺤѧѧѧﻀﺮﻳﻦ ﺑﺎ
  .ة ﻓﺌﺮان ﻣﺆﻧﺜﺔ وﻣﺬآﺮﻳﻦ ﺑﺎﺳﺘﺨﺪام اﻟﻤﺴﺘﺤﻀﺮ
  - :ﻨﻬﺠﻴﺔ اﻟﺒﺤﺚﻣ 
  -: دراﺳﺔ اﻟﺜﺒﺎﺗﻴﺔ 
  -:ﺗﻢ ﺣﻔﻆ اﻟﻤﺴﺘﺤﻀﺮﻳﻦ ﺗﺤﺖ ﻇﺮوف ﻣﻨﺎﺧﻴﺔ ﻣﺨﺘﻠﻔﺔ 
  ،%57 ْ م ورﻃﻮﺑﺔ ﻧﺴﺒﻴﺔ 52 درﺟﺔ ﺣﺮارة (1)ﻏﺮﻓﺔ ﺣﻔﻆ رﻗﻢ 
 %57 ْ م ورﻃﻮﺑﺔ ﻧﺴﺒﻴﺔ 03 درﺟﺔ ﺣﺮارة (2)ﻏﺮﻓﺔ ﺣﻔﻆ رﻗﻢ 
  %.57 م ورﻃﻮﺑﺔ ﻧﺴﺒﻴﺔ  ْ53 درﺟﺔ ﺣﺮارة (3)ﻏﺮﻓﺔ ﺣﻔﻆ رﻗﻢ  و
ﺗﻢ ﺗﻄﺒﻴﻖ ﻃﺮﻳﻘѧﺔ اﻟﻔѧﺼﻞ اﻟﻜﺮوﻣѧﺎﺗﻮﻏﺮاﻓﻲ ﻋﻠѧﻰ اﻟﻤﺴﺘﺤѧﻀﺮﻳﻦ ﺑﻌѧﺪ ﺣﻔﻈﻬﻤѧﺎ ﺗﺤѧﺖ ﻇѧﺮوف ﻣﻨﺎﺧﻴѧﺔ ﻣﺨﺘﻠﻔѧﺔ وذﻟѧﻚ 
واﻟﻄѧﻮر اﻟﻤﺘﺤѧﺮك أﺳѧﻴﺘﻮﻧﺎﻳﺘﺮﻳﻞ و ﻣﺤﻠѧﻮل اﻟﻔﻮﺳѧﻔﺎت اﻟﻤﺘﻌѧﺎدل ﺑﻄﺮﻳﻘѧﺔ ( 81C)ﺑﺎﺳﺘﺨﺪام ﻋﻤﻮد اﻟﻔѧﺼﻞ اﻟﻜﺮﺑѧﻮﻧﻲ 
  . ﻧﺎﻧﻮﻣﻴﺘﺮ ﻟﻤﺴﺘﺤﻀﺮ ﻣﺨﻠﺐ اﻟﻘﻂ542اﻟﻔﺼﻞ اﻟﻤﺘﺪرج وﻃﻮل ﻣﻮﺟﻲ  
 % 06 آﺤѧﻮل ﻣﺜﻴﻠѧﻲ  ﻳﺘﻜѧﻮن ﻣѧﻦ  وﻃﻮر ﻣﺘﺤѧﺮك 81C()ﺴﺒﺔ ﻟﻤﺨﻠﺐ اﻟﺸﻴﻄﺎن ﻓﻘﺪ ﺗﻢ اﺳﺘﺨﺪام ﻋﻤﻮد اﻟﻔﺼﻞ أﻣﺎ ﺑﺎﻟﻨ 
  . ﻧﺎﻧﻮﻣﻴﺘﺮ872ﻃﻮل ﻣﻮﺟﻲ و %04ﺎء ﻣو
ﺘﺼﺎص اﻟﺬري ، واﻟﺘﺤﻠﻴﻞ اﻟﺠﺮﺛﻮﻣﻲ ﺑﺎﺳﺘﺨﺪام ﻃﺮﻳﻘѧﺔ اﻟﻌѧﺪ ﻣاﻟﻌﻨﺎﺻﺮ اﻟﻤﻌﺪﻧﻴﺔ ﻓﻘﺪ ﺗﻢ ﺑﺎﺳﺘﺨﺪام ﺟﻬﺎز اﻻ أﻣﺎ ﺗﺤﻠﻴﻞ 
  .اﻟﺠﺮﺛﻮﻣﻲ اﻟﻜﻤﻲ
  -: دراﺳﺔ اﻟﺴﻤﻴﺔ 
 أﺳѧﺎﺑﻴﻊ ﻟѧﺪرﺟﺎت 7-6 وﻳﺘѧﺮاوح ﻋﻤﺮهѧﺎ ﻣѧﻦ ﻧѧﺎثإذآѧﻮر ون اﻟﺴﻮﻳѧﺴﺮﻳﺔ اﻟﺒﻴѧﻀﺎء ﻣѧﻦ اﻟﺠﻨѧﺴﻴﻦ ﺳѧﺘﺨﺪام اﻟﻔﺌѧﺮاإﻢ ﺗѧ
  .ﺳﻤﻴﺔ ﺣﺎدة ، ﺗﺤﺖ اﻟﺤﺎدة و ﻣﺰﻣﻨﺔ: اﻟﺴﻤﻴﺔ اﻟﻤﺨﺘﻠﻔﺔ 
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  -:اﻟﻨﺘﺎﺋﺞ 
  -:دراﺳﺎت اﻟﺜﺒﺎﺗﻴﺔ 
  -:ﺧﺘﺒﺎرات اﻟﻔﻴﺰﻳﺎﺋﻴﺔ ﻹا
  .ﺧﺘﺒﺎرات ﺗﻐﻴﺮ ﻟﻮن ﻣﺤﺘﻮﻳﺎت اﻟﻜﺒﺴﻮﻻتﻹأﻇﻬﺮت ا
  -:ﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺧﺘﺒﺎرات اﻹا
أﺛﺒﺘﺖ اﻟﺪراﺳﺔ ﺻﺤﺔ ودﻗﺔ و ﻣﺼﺪاﻗﻴﺔ ﻃﺮق اﻟﻔﺼﻞ اﻟﻜﺮوﻣﺎﺗﻮﻏﺮاﻓﻲ ﻓﻲ ﻓﺼﻞ اﻟﻤﻮاد اﻟﻔﻌﺎﻟﺔ ﻋﻦ اﻟﻤѧﻮاد اﻟﻤѧﻀﺎﻓﺔ 
  .ﺴﻴﺮ ﻟﻜﻞ ﻣﻦ اﻟﻤﺴﺘﺤﻀﺮﻳﻦﻜﻟﻠﻤﺴﺘﺤﻀﺮﻳﻦ ، وﻗﺪ ﺗﻢ ﺗﻘﺪﻳﺮ ﻣﻌﺎﻣﻞ اﻟﺘﻔﺎﻋﻞ وﻣﻨﺘﺼﻒ اﻟﻌﻤﺮ وﻣﻌﺎﻣﻞ اﻟﺘ
 ﻣѧﻦ ﻋﻨѧﺼﺮ اﻟѧﺼﻮدﻳﻮم وآﻤﻴѧﺔ آﺒﻴѧﺮة ﻣѧﻦ ﻋﻨﺎﺻѧﺮ أﻣﺎ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻌﻨﺎﺻﺮ اﻟﻤﻌﺪﻧﻴﺔ أﺛﺒﺘﺖ اﻟﺪراﺳﺔ وﺟﻮد ﻧﺴﺒﺔ ﺿѧﺌﻴﻠﺔ 
وأﺛﺒﺘѧѧﺖ اﻟﺪراﺳѧѧﺎت . اﻟﻤﺎﻏﻨﻴѧѧﺴﻴﻮم واﻟﺒﻮﺗﺎﺳѧѧﻴﻮم واﻟﻜﺎﻟѧѧﺴﻴﻮم وﻟѧѧﻢ ﻳﻜѧѧﺸﻒ ﻋѧѧﻦ وﺟѧѧﻮد ﻋﻨﺎﺻѧѧﺮ ﺳѧѧﺎﻣﺔ ﺑﺎﻟﻤﺴﺘﺤѧѧﻀﺮﻳﻦ 
  . ﺧﻼل ﻓﺘﺮة اﻟﺪراﺳﺔﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﺒﻜﺘﻴﺮﻳﺎ اﻟﻬﻮاﺋﻴﺔ واﻟﻔﻄﺮﻳﺎت ﻋﺪم ﺗﻐﻴﺮ اﻟﻌﺪ اﻟﺠﺮﺛﻮﻣﻲ اﻟﻜﻤﻲ اﻟﻤﺎﻳﻜﺮوﺑﻴﻮﻟﻮﺟﻴﺔ
  -:دراﺳﺎت اﻟﺴﻤﻴﺔ 
اﻟﺪراﺳѧﺔ ﻧﻘѧﺺ ﻣﻠﻤѧﻮس ﻓѧﻲ ﻋѧﺪد آﺮوﻳѧﺎت اﻟѧﺪم اﻟﺒﻴѧﻀﺎء ﻟﻤﺴﺘﺤѧﻀﺮ ﻣﺨﻠѧﺐ اﻟﻘѧﻂ ﻓѧﻲ ﺣﺎﻟѧﺔ اﻟѧﺴﻤﻴﺔ اﻟﺤѧﺎدة أﻇﻬﺮت 
 أﻣѧﺎ ﻓѧﻲ ﺣﺎﻟѧﺔ اﻟѧﺴﻤﻴﺔ ﺗﺤѧﺖ اﻟﺤѧﺎدة واﻟﻤﺰﻣﻨѧﺔ ﻓﻠѧﻢ ﺗѧﺴﺠﻞ أي )TSA,TLA(ﺰﻳﻤѧﺎت اﻟﻜﺒﺪﻳѧﺔ اﻻﻧ ﻣﻌѧﺪل  وارﺗﻔﺎع ﻓѧﻲ 
  .ﻣﻼﺣﻈﺎت ﺗﺬآﺮ
  - :اﻟﺨﻼﺻﺔ
  -:ن ﻋﻨѧﺪ ﺣﻔﻈﻬﻤѧﺎ ﻓѧﻲ اﻟﻈѧﺮوف اﻟﻤﻨﺎﺧﻴѧﺔ اﻟﺘﺎﻟﻴѧﺔ ﺎﺗﻴѧﺔ ﻣﺴﺘﺤѧﻀﺮي ﻣﺨﻠѧﺐ اﻟﻘѧﻂ وﻣﺨﻠѧﺐ اﻟѧﺸﻴﻄﺎ ﺛﺒﺑﻴﻨѧﺖ اﻟﺪراﺳѧﺎت 
  .رﻃﻮﺑﺔ ﻧﺴﺒﻴﺔ% 57م وº53، º03 ،º52
  .وﻗﺪ ﺧﻠﺼﺖ اﻟﺪراﺳﺔ اﻟﻰ أن ﻣﺴﺘﺤﻀﺮ ﻣﺨﻠﺐ اﻟﻘﻂ ﻳﺠﺐ أن ﻳﻮﺿﻊ ﻓﻲ ﻇﺮوف اﻟﺤﻔﻆ اﻟﻤﻮﺻﻰ ﺑﻬﺎ
آﻤѧﺎ  .ي أﺿѧﺮارﺑﺎﻟﺨﻼﻳﺎ ﺎن ﻷﺆدﻳѧ ﻳ ﻻ أﺛﺒﺘﺖ دراﺳѧﺎت اﻟѧﺴﻤﻴﺔ اﻟﺤѧﺎدة أن ﻣﺴﺘﺤѧﻀﺮي ﻣﺨﻠѧﺐ اﻟﻘѧﻂ وﻣﺨﻠѧﺐ اﻟѧﺸﻴﻄﺎن 
 اﻟѧﺪم واﻟﻜﻴﻤﻴѧﺎء اﻟﺤﻴﻮﻳѧﺔ أن اﻟѧﺴﻤﻴﺔ اﻟﻤﺰﻣﻨѧﺔ ﻟﻤﺨﻠѧﺐ اﻟﻘѧﻂ و ﻣﺨﻠѧﺐ اﻟѧﺸﻴﻄﺎن ﻻ ﺗѧﺆدي ﻷي ﺗﻐﻴѧﺮات  دراﺳѧﺎت أﺛﺒﺘﺖ
  . ﺎﻳ أﺿﺮار ﺑﺎﻟﺨﻼ أيﺟﺬرﻳﺔ آﻤﺎ ﻟﻢ ﺗﺆد إﻟﻰ
 اﻟﻤﻨﺨﻔﻀﺔ ﻟﻤﺨﻠﺐ اﻟﻘﻂ و ﻣﺨﻠﺐ اﻟﺸﻴﻄﺎن آﻤﺎ ﻳﻈﻬﺮهﺎ ﺛﺒﺎت اﻹﻧﺰﻳﻤﺎت اﻟﻜﺒﺪﻳﺔ وﺳѧﻼﻣﺔ اﻷﻋѧﻀﺎء اﻟﺤﻴﻮﻳѧﺔ  اﻟﺴﻤﻴﺔ
  .واﺳﻊ ﻟﻠﺠﺮﻋﺎت اﻟﻌﻼﺟﻴﺔ ﻟﻜﻞ ﻣﻦ اﻟﻤﺴﺘﺤﻀﺮﻳﻦﺗﺒﻴﻦ وﺟﻮد هﺎﻣﺶ ﺳﻼﻣﺔ 
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1.  Introduction and Literature Review 
 
 
1.1. The importance of natural plants and herbal remedies 
 
        Natural plants and herbs have great importance for hundreds of years. Most of 
herbal remedies are sold in many countries with medicinal claims or as food 
supplements, and are available in different forms (e.g. tea, liquids, and dry extracts, in 
pills or capsules). Unfortunately, side effects have been found and there is evidence of 
serious hazards as a result of ignorance. Furthermore, with many herbal medicines their 
mode of action is not fully understood. To provide information, full background 
knowledge of quality, safety and efficacy of plants or herbal remedies is required. 
        Regulations covering herbal medicine are highly required to ensure that quality, 
safety and efficacy are harmonized. Manufacturers and suppliers of herbal products 
should adhere to quality control standards and good manufacturing practices. 
1.1.1 Quality 
        Quality is a significant concern for manufacturers and those who care for human 
health. It relates to the processes involved in maintaining the integrity of the products 
during extraction and other processes in manufacturing. Fortunately, it has been proved 
possible to apply quality control methods appropriate for most herbal and plant 
products. Without such methods there is no assurance that the herb contains what is 
claimed on the label. 
         Establishing identification test for the  raw herbal material is the first step in 
conducting quality control of herbal products. It is important to realize that different 
batches of the same herb may contain different ingredients due to the regional, climatic, 
agricultural, and environmental factors. In addition, some of the active ingredients are 
not known. Therefore, all herbal products should undergo qualitative and quantitative 
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investigations to identify and determine all of the herbal constituents. These tests 
require use of chromatographic techniques such as thin layer chromatography, gas 
chromatography and high performance liquid chromatography, and fingerprint 
instrumentation can provide full identification of chemicals contained in the plant or 
extract. 
1.1.2 Safety 
        The safety of the medicinal products is essential for overall health and avoids any 
risk to humans. Manufacturers of herbal remedies should carry out clinical trials to 
prove safety. These trials are based on two types of investigations: toxicity and any 
pathogenic contaminations. Among the toxic contaminants are heavy metals e.g. lead, 
mercury, cadmium and arsenic. 
        Four points must be emphasized to assure the safety of an herbal drug. Any 
adverse effects caused by herbal ingredients, such as allergic, cardiac, hepatic and 
nephrotic effects. Advice should be given before taking herbal drugs during pregnancy 
and breast feeding. Any herbal ingredients that have the potential to interfere with any 
drug should be identified. And lastly the dosage recommended in the label should not 
be exceeded. 
1.1.3 Efficacy 
         It is very clear that herbal remedies are widely used. This degree of popularity 
high lighted the need for the determination of the efficacy of all herbal medicines. The 
pharmacological activities for only few herbs are investigated; there is, at present, no 
full documentation for many of them. This is due to the difficulty of conducting 
suitable validating trials of efficacy. Scientific validation of efficacy requires a number 
of factors to be considered. Firstly, photochemical data are required to identify the 
chemical constituents and provide a useful indication of their pharmacological 
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properties. Secondly, in vitro, or in-vivo animal studies often provide only the 
information regarding any pharmacologically active substances. Thirdly, clinical data 
require long term clinical trials to minimize the influence of patient and therapist 
expectations. These trials should be conducted against placebo or reference medication 
that already exists. Finally, extraction into an aqueous medium or formulation of a plant 
product may affect the properties of therapeutic herbal ingredients. Generally, herbal 
ingredients should have documented photochemical and pharmacological data 
supporting the traditional use, and such data must be correlated with adequate quality 
and safety studies. (Ernest, 2000). 
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1.2  What is Cat's claw? 
 
 
        Cat’s claw (Uncaria tomentosa (Wild). D.C.) is known with the common names 
Cat's Claw, Una de gato, Una de gavilan and Hawk's claw. The root, bark and leaves 
are used medicinally. The following properties are attributed to Cat’s claw: 
antibacterial, ant mutagenic, antioxidant, anti-inflammatory, antitumorous, antiviral, 
cytostatic, depurative, diuretic, hypotensive, immunostimulant, and vermifuge 
(Ocampo and Palmiro 1994; Taylor 1998; Gonclves et al. 2005).  
        Una de Gato or Cat’s claw is a large woody vine that is indigenous to the Amazon 
Rainforest and other tropical areas of South and Central America including Peru, 
Columbia, Ecuador, Guyana, Trinidad, Venezuela, Suriname, Costa Rica, Guatemala, 
and Panama. Its name is derived from the hook-like thorns that grow along the vine that 
resemble a claw of a cat. Uncaria tomentosa (Rubiaceae) is a large woody vine about 
100 feet high with claw like thorns and small yellowish-white flowers. It has been used 
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medicinally by the Aguaruna, Asháninka, Cashibo, Conibo and Shipibo tribes of Peru 
for at least 2,000 years (Jones 1995). 
         Cat’s claw is traditionally used to treat asthma, inflammations of the urinary tract, 
to recover from childbirth, as a kidney cleanser, to cure deep wounds, for arthritis, 
rheumatism and bone pain, to control inflammation and gastric ulcers, and for cancer 
(Krallendorn-IPDC 1995).  
         Indigenous tribes also use Cat’s claw to treat tumors, inflammations, rheumatism 
and gastric ulcers, gonorrhea and dysentery. Some tribes use Cat’s claw to treat 
diabetes, urinary tract cancer in women, cirrhosis, gastritis, rheumatism, and tumors. 
Some people in Peru believe that Cat’s claw "normalizes the body" and have used it 
since ancient times to treat fevers, abscesses and to cleanse the system. Other 
documented indigenous uses in Peru include using this important vine for hemorrhages, 
impurities of the skin, as a blood cleanser, and for irregularity of the menstrual cycle 
(Kiplinger 1993; Urbina 1994; Aquino 1991).  
In Austria and Germany detailed work on the alkaloid extraction methods and the 
immunostimulating actions of these alkaloids from Cat’s claw was done. In May 1994, 
the World Health Organization sponsored the First International Conference on Cat’s 
claw in Geneva, Switzerland. At the conference, Cat’s claw received official 
recognition as a medicinal plant and it was pointed out that not since quinine was 
discovered in the bark of a Peruvian tree in the 17th century, has any other rainforest 
plant ever prompted such worldwide attention (Kiplinger 1993; 1994; Heitzman et al. 
2005).  
        Cat’s Claw capsules registered and marketed in Saudi Arabia, manufactured by 
Sun Natural, USA. The therapeutic dose is one capsule twice daily or as suggested by 
the physician. The active ingredient per capsule is Cat's claw 350 mg. The excipients 
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added in the formulation were Magnesium Stearate 12.5 mg/capsule and Maltodextrin 
167.5 mg/capsule, the total weight of capsule was 530 mg. The capsule contains Cat’s 
claw with main active compound isomitraphylline. The structural formula of 
isomitraphylline and its uses are shown in Table1.1. 
Table1.1: The main active ingredient in Cat’s claw and its main use. 
SUBJECT INFORMATION 
Name of the herbal medicine Cat' s Claw 
Main active marker Isomitraphylline 
Structural formula 
 
 
 
 
 
 
 
 
Main use 
Anti-inflammatory, anti-rheumatic and 
analgesic 
Recommended dose: One capsule to be taken once or twice a day. During times of 
special need, dosages can be increased to two capsules two to three times per day.  
1.2.1 Constituents of Cat's claw 
         Several biologically active natural compounds were isolated from Cat’s claw:  
3β, 6β, 7-acetoxydihydronomiline, 5α-carboxystrictosidine, acetyluncaric-acid, adipic-
acid,19α-trihydroxy-urs-12-en-28-oic-acid, alloisopteropodine, allopteropodine, 
angustine, campesterol, carboxystrictosidine, catechol, d-catechin, dl-catechol, 
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catechutannic acid, β-sitosterol, corynantheine, corynoxeine, dihydrocorynantheine, 
dihydrocorynantheine- N-oxide, dihydrogambirtannine, ellagic acid, l-epicathechol, (-)-
epicathechin, gallic-acid, hanadamine, hirsutine, hirsuteine, hirsutine-N-oxide, hyperin, 
3-iso-19-epi-ajmalicine, isocorynozeine, isomitraphylline, isopteropodine, 
isorhynchophylline, isorhynchophylline-N-oxide, isorotundifoline, ketouncaric-acid, 
mitraphylline, 11-methoxyyohimbine, oleanolic-acid, ourouparin, oxogambirtannine, 
pteropodine, quinovic-acid-3β-O-(β-d-glucopyranosyl -(1->3) β-d- fucopyranosyl-(27-
>1)β d-glucopyranosyl-ester, quinovic-acid-3 β-O-β-d-fucopyranoside, quinovic-acid-3 
β-O-β-d-fucopyranosyl-(27->1) β-d-glucopyranosylester, quinovic-acid-3 β-O-β-d-
quinovopyranoside, rhynchophylline, rotundifoline, speciophylline, stigmasterol, 
uncarine, uncarine-f,  ursolic-acid and quinic acid (Ocampo 1994; Jones 1995; DeFeo 
1992; Duke 1994; Yepez 1991; Kiplinger 1993; Urbina 1994; Wagner 1985; Wagner 
1995; Laus and Kiplinger 1994; Aquino 1990; Cerri 1988; DeSimone 1988; 
Monograph Cat’s claw 1996; Montenegro De Matta 1976; Sheng et al. 2005). Kitajima 
et al. (2003) isolated two new 27-nor-triterpene glycosides, tomentosides A and B from 
Cat’s claw. Furthermore, a new glucoalkaloid, 3, 4-dehydro-5(S)-5-
carboxystricotosidine was also isolated and its synthesis and absolute configuration was 
reported (Kitajima et al. 2000, 2002 and 2003). Recently Sheng et al. (2005) reported 
an active ingredient from the water extract of Cat's Claw. 
1.2.2 Medicinal uses of Cat's claw:  
         The most attention to date has been on the oxindole alkaloids found in the bark 
and roots of Cat’s claw which have been documented to stimulate the immune system 
(Kiplinger 1994). Studies indicated at least six of these oxindole alkaloids can increase 
immune function by up to 50% in relatively small amounts (Kiplinger 1989; 1994; 
Sheng et al. 1998; Lemaire et al. 1999; Sheng et al. 2000). This has led to its use around 
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the world as an adjunctive treatment for cancer and AIDS as well as other diseases 
which negatively impact the immunological system. In addition to its 
immunostimulating activity for cancer patients, other anti-cancerous properties have 
been documented on the alkaloids as well as other constituents in Cat’s claw (Kiplinger 
1989; Stuppner 1992; Winkler et al. 2004).  
         Five of the oxindole alkaloids have been clinically documented with anti-
leukemic properties, and various root and bark extracts have demonstrated anti-
tumorous and antimutagenic properties (Stuppner 1992; Rizzi 1993). Based on different 
studies Cat’s claw was suggested to be used for accelerating recovery of patients from 
leucopenia (Akesson et al. 2003). Reports on observatory trials with cancer patients 
taking Cat’s claw in conjunction with traditional cancer therapies like chemotherapy 
and radiation reported fewer side effects to the traditional therapies like hair loss, 
weight loss, nausea, secondary infections and skin problems.  
         Another significant area of study on Cat’s claw has focused on its anti-
inflammatory properties (Recio 1995). While plant sterols like β-sitosterol, acids and 
other antioxidants found in Cat’s claw account for some of these properties, Quinovic 
acid glycosides found in the bark and roots of Cat’s claw were found to be the most 
potent anti-inflammatory constituents found in the plant. These studies indicated that 
Cat’s claw and some of its constituents could inhibit inflammation from 46% up to 89% 
in various in vivo and in vitro tests and supported its use in arthritis and rheumatism as 
well as other types of inflammation associated with various stomach disorders and 
ulcers. This same group of chemicals also demonstrated in vitro antiviral properties 
(Aquino 1989, Aguilar et al. 2002, Miller et al. 2001). Cat’s claw was found to be an 
effective scavenger of free radicals. Its anti-inflammatory actions appeared to be due to 
immunomodulation via suppression of TNF alpha synthesis, (Sandoval et al 2002). 
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         Cat’s claw also contains the alkaloids, Rhynchophylline, Hirsutine, and 
Mitraphylline, which have demonstrated hypotensive and vasodilating properties. 
Rhynchophylline has been also shown to inhibit platelet aggregation and thrombosis 
and may help prevent blood clots in blood vessels, as well as to relax the blood 
vessels of endothelial cells, dilate peripheral blood vessels, lower the heart rate and 
lower blood cholesterol (Chan-Xun 1992).  
In herbal medicine today, Cat’s claw is employed around the world for many different 
conditions: for the treatment of immune disorders, gastritis, ulcers, cancer, arthritis, 
rheumatism, irregularities of the female cycle, acne, organic depression, wounds, 
fungus, fistulas, hemorrhoids, rheumatic disorders, neuralgias, chronic inflammation 
(vaginal or intestinal), and viral diseases like herpes zoster (shingles) (Heitzman et al. 
2005).  
         Cat’s claw has the ability to cleanse the entire intestinal tract and is known to be 
effective in treating stomach and bowel disorders such as Crohn's disease, leaky 
bowel syndrome, ulcers, gastritis, diverticulitis and other inflammatory conditions of 
the bowel, stomach and intestine. Some workers recommended Cat’s claw for its 
immune stimulating effects, for cancer, in heart problems to help prevent strokes and 
heart attacks and to reduce blood clots, for diverticulitis and irritable bowel syndrome 
(Yano 1991; Jin 1991, Sheng 2000).  
         Some nutritionists consider Cat’s claw being beneficial in the treatment of 
cancer, arthritis, bursitis, rheumatism, genital herpes and herpes zoster, allergies, 
ulcers, systemic candidiasis, PMS and irregularities of the female cycle, 
environmental toxin poisoning, numerous bowel and intestinal disorders, organic 
depression and HIV. Some others cited its usefulness in treating diverticulitis, 
hemorrhoids, peptic ulcers, colitis, gastritis, parasites and leaky bowel syndrome 
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(Kiplinger 1993; Yano 1991). Toxicity studies performed showed no toxicity for 
Cat’s claw at the dosages used (Santa Maria 1997).  
1.2.3 Published HPLC methods for the determination of the oxindole 
alkaloids: 
Ganzera et al (2001) adopted a method to determine the oxindole alkaloids by HPLC 
using C18 column and mobile phase 10mM phosphate buffer pH 7.0 and acetonitrile 
at a wave length of 245 nm. 
 Rita de C.A et al (2008) described a method for the determination of the oxindole 
alkaloids in Uncaria tomentosa and Uncaria guianesis using C18 column, mobile 
phase 45% of MeCN and 55% of 30mM NH4OAC solution pH adjusted to 6.8-7.0, 
wavelength of detection is 245 nm. 
The literature showed no stability studies for Cat's claw capsules. 
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1.3 What is Devil's claw? 
 
                         
          Devil’s claw (Harpogophytum procumbent D. C.) is a plant with bright pinkish 
red flowers native of south and southwestern Africa, Kalahari deserts, Namibia and 
island of Madagascar. The name of Devil’s claw is derived from the herb’s unusual 
fruits, which seem to be covered with numerous small hooks.  
         The secondary storage roots, or tuber, of the plant is employed in herbal 
supplements (Tyler 1993). Devil’s claw is used in rheumatoid arthritis, indigestion 
and heartburn (Weiss 1988). The tuber is mostly used as remedy (Pahlow 1993; 
Mabey 1988) for gall bladder, liver, and kidney problems, but western herbalists use 
them mostly in the treatment of rheumatic pain and joint problems, mainly arthritis 
and lumbago (Pahlow 1993, Mabey 1988; Ody 1993; Chrubasik 1997; Gegnier et al. 
2004). Devil’s claw may also be used as a lymphatic system stimulant to help 
detoxify the entire body (Argus 2000). It has a cooling energy with bitter and 
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astringent taste, and is considered as an alternative, anti-inflammatory and analgesic 
herb (Frawley and Lad 1986; Mahomed and Ojewole 2004; Catelan et al. 2006). The 
analgesic properties can be compared in strength to cortisone or phenylbutazone. It is 
prescribed for the treatment of rheumatoid and osteoarthritis with serious side effects 
(Mabey 1988; Ody 1993). 
         Devil's claw capsules registered and marketed in Saudi Arabia, manufactured by 
Bioron, France. The therapeutic dose is one capsule twice daily or as suggested by the 
physician. The active ingredient per capsule in Devil's claw is 189 mg. The excipients 
added in the formulation are magnesium Stearate 5 mg/capsule, precipitated silica (5 
µm) 8 mg/capsule and precipitated silica (3-4 µm) 2 mg/capsule. The total weight of 
capsule is 204 mg. The capsule contains Devil's claw with main active compound 
harpagoside. The structural formula of harpagoside and its uses are shown in Table 
2.1. 
Table 2.1: The main active ingredient in Devil’s claw and its main use. 
SUBJECT INFORMATION 
Name of the herbal medicine Devil's  Claw 
Main active marker  Harpagoside 
Structural formula O
OH
OHHO
OH
O
O
O
HO OH
H
 
Main use 
Anti-inflammatory, anti-rheumatic and 
analgesic 
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1.3.1 Constituents of Devil's claw 
 
        The following natural products were isolated from the rhizome of Devil’s claw: 
Iridoid glycosides, including harpagide, harpagoside and procumbide; 8-p-
coumaroylharpagide, 8-feruloylhargide, 8-cinnamoylmyoporoside, pagoside,  as 2, 6-
diacetylacteoside, 6-acetylacteoside. Falconoid, mainly kaempferol and luteolin 
glycosides; phenolic acids; chlorogenic, caffeic acid and cinnamic acid; a quinone, 
harpagoquinone; and other miscellaneous compounds including  triterpenes, sterols, 
oleanolic and ursolic acid derivatives, esters, and sugars (Boje et al. 2003; 
Munkombwe 2003).  
        The active constituent of Devil’s claw tuber contains three important constituents 
belonging to the Iridoid glycoside family: harpagoside, harpagide, and procumbide. 
The secondary tubers of the herb contain twice as much harpagoside as the primary 
tubers. As such, these secondary tubers contain the preferable concentration of active 
ingredients (Leung and Foster 1986). Harpagoside and other Iridoid glycosides found 
in the plant may be responsible for the herb’s anti-inflammatory and analgesic 
actions. In Europe, doctors treat some conditions like arthritis with an injection of 
Devil’s claw extract (Chrubasik 2004).  
         The active principle in Devil’s claw, which is used to standardize products, is a 
glycoside called harpagoside. Other constituents include beta-sitosterol, harpagide, 
procumbine, sugars, gum resin (Mabey 1988) and bitter principles (Pahlow and Das 
1993). Devil’s claw tubers should have at least 1.2 % harpagoside to be considered for 
use as a herbal medicine (Chrubasik 1997). Both standardized extracts and whole herb 
preparations can be used. The isolated harpagoside is not preferable to a whole plant 
extract (Mabey 1988), because, although the mechanism of action is not yet fully 
understood, research has shown when a whole herb extract is combined with 
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harpagoside, a greater reduction of inflammatory mediators is seen than with 
harpagoside alone (Chrubasik,1997). 
        The recommended dosage of the whole herb is 1.5 to 3 grams in decoction three 
times a day. For tablets and capsules, the daily dosage should total up to 50 mg 
harpagoside. This may mean taking up to 2400 mg of powdered herb in divided doses 
three times a day (Chrubasik, 1997). Due to considerable variation in the 
concentration of active constituents of Devil’s claw the quality control studies on the 
finished herbal drug formulations from all the companies is highly recommended 
(Chrubasik 1997). Devil’s claw needs to be taken continuously for up to 4 weeks 
before noticeable improvement in pain relief is felt (Pahlow 1993; Chrubasik 1997). It 
can be combined with other anti-inflammatory or cleansing herbs like Angelica (A. 
archangelic), celery seed (Apium graveolens) or nettles (Urtica dioica) (Chrubasik 
1997; Ody 1993). Some workers did not support the use of Devil’s claw in arthritis. 
However, for arthritis treatment, several herbalists are known to combine Devil’s 
claw with Bog bean or Meadowsweet as well to get the desirable effect (Whitehouse, 
1983; Graham and Robinson 1981). Devil’s claw extract was also found useful in 
arthrosis of hip and knee (Wagener and Lupke 2003).  
1.3.2 Medicinal uses of Devil's claw  
         It is widely believed that so far modern medicine has not produced a superior 
anti-inflammatory medication to Devil’s claw. Most non-steroidal anti-inflammatory 
drugs (NSAIDs) act by inhibiting prostaglandin synthesis. Several studies indicate 
that Devil’s claw does not appear to act in this way (Moussard 1992; Whitehouse 
1983). Each allopathic anti-inflammatory has its own profile of side effects ranging 
from stomach disorders to serious blood abnormalities. Pain relief may occur more 
quickly, but in the long run, the natural treatment of chronic joint disease with Devil’s 
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claw is better for the body with results as good as any allopathic anti-inflammatory 
medication. The anti-inflammatory properties of Devil’s claw capsules are attributed 
to two constituents: harpagoside and β-sitoserol. Devil’s claw capsules or tablets as a 
remedy needs proper attention regarding its harpagoside content. 
         The second major area of use is in the digestive system where it is used as a 
tonic. Absorption of nutrients from the gut is improved and from that the body begins 
to be better nourished at all levels. The bitter taste is vital for this action, improving 
the function of the liver in absorption of nutrients and in cleansing and de-toxifying 
the body. The gall bladder is stimulated to release bile so that conditions such as 
constipation are relieved. Research in Germany has found improvement in conditions 
of the upper duodenum related to the pancreas (Zimmerman 1977) and clinical 
evaluation has indicated a marked reduction in raised cholesterol levels. 
         In a recent medical study, 118 patients with chronic back pain seeking treatment 
for acute attacks of pain were included in a four week randomized double-blind trial 
into the effectiveness of Devil’s claw. The supplementary use of a pain-relieving drug 
was permitted during the study. At the end of the trial 9 out of the 51 people receiving 
Devil’s claw were pain free compared with 1 of the 54 receiving placebo. The Devil’s 
claw group experienced greater reduction in pain generally than the placebo group, 
but this was considered of borderline significance statistically (Chrabasik 1997). 
        There are no known side effects from Devil’s claw when used in the correct 
doses. Although it has been used to relieve certain stomach and digestive problems, it 
is not recommended if ulcers are present (Pahlow 1993). In the literature one report 
mentioned that Devil’s claw has the potential to stimulate uterine muscle and 
therefore, should not be used during pregnancy (Mabey 1988). This may be due to the 
glycosides or the bitter principles present in the plant. 
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        Devil’s claw is also considered by herbalists to be a potent bitter. Bitter 
principles, like the Iridoid glycosides found in Devil’s claw are known to stimulate 
the stomach to increase the production of acid, thereby helping to improve digestion. 
Because Devil’s claw promotes stomach acid, anyone with gastric or duodenal ulcers 
should not use the herb. Generally daily dose of harpagoside is suggested for pain 
relief. Devil's claw has been found to be well tolerated when used daily for up to 16 
weeks. However, it may interfere with drugs such as: antiacids, antidiabetes drugs and 
antihypertensive drugs (Chrubasik, 2004).  
1.3.3  Published HPLC methods for the determination of 
Harpagoside 
Guillerault (1994) adopted a high performance liquid chromatographic method for 
determining Harpagoside and other two glycosides by using methanol/water as mobile 
phase, RP 18 column and UV detector. 
Yang, (2009) described a high performance liquid chromatographic method for the 
determination of five compounds scrophularia ningpoenis, column was C18, the 
mobile phase was acetonirile-0.4% acetic acid in a gradient elution. The UV detector 
wavelength was set at 280 nm for harpagoside. 
Li P, (2007) described a method for simultaneous determination of harpagoside and 
cinnamic acid in rat plasma by high-performance liquid chromatography. Separation 
was achieved on a Kromasil C18 column, and detection was by UV absorption at 272 
nm. 
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1.4 Stability of Medicinal Products 
          The stability of a product relates to its resistance to the various chemical, 
physical and microbiological reactions that may change the original properties of the 
preparation during transport, storage and use. Other criteria of stability are the effects 
of such changes on the fitness of the product for use as a medicine. Stability is often 
expressed in quantitative terms as the shelf-life that is the time during which the 
medicinal product is predicted to remain fit for its intended use under specified 
conditions of storage. The shelf-life of a medicinal product kept in its closed container 
under specified conditions is commonly defined as the time from manufacture or 
preparation until the original potency or content of active constituent has been 
reduced by 10%. This time is known as the t10%or t 90%. For most products, this 10% 
limit of chemical degradation is usually considered to be acceptable in practice but 
more stringent limits may need to be imposed if the degradation products are more 
toxic or irritant than is the drug. Although it is often convenient to express shelf-life 
solely in terms of the chemical stability of the active constituent, it is essential that the 
other desirable properties of the product are retained during storage. 
1.4.1 Chemical stability 
         Chemical degradation of the active constituent in a medicinal product often 
results in a loss in potency; for example, hydrolysis of penicillin results in a lower 
antimicrobial activity. In a few instances the degradation products of a drug may be 
toxic (for example, epianhydrotetracycline formed from tetracycline or free amines 
produced by degradation of iodipamide) so that clinical use of preparations may be 
unacceptable if the extent of decomposition is relatively great. Degradation of an 
excipients can pose problems of physical or microbiological stability. For example, 
hydrolysis of a sorbitan ester may result in sufficient loss in its ability to produce an 
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interfacial film that a formulated emulsion may crack; hydrolysis of an antimicrobial 
preservative such as methyl hydroxybenzoate can reduce the concentration so that it 
can no longer inhibits the growth of micro-organisms. Marked discoloration of 
solution that contains adrenaline may represent only a very slight change in drug 
content but is unacceptable to the patient, pharmacist, physician and nurse. In general, 
chemical reactions proceed more readily in the liquid state than in the solid state so 
that serious stability problems are more commonly encountered in liquid medicines; 
the stability of suspensions of solid drugs in water or other liquids is usually greater 
than that of solutions. In this section, the various types of reactions that cause 
chemical degradation of medicines are considered together with the principal factors 
that affect the rate. 
1.4.2 Chemical Reactions that Cause Degradation 
        A variety of chemical reactions can result in the degradation of drug substances 
and excipients; the most common reactions are mentioned below:  
1. Hydrolysis 
         Hydrolysis involves the reaction of a molecule with water that results in 
cleavage.  
2. Dehydration 
         Dehydration reactions occur occasionally in drugs. An example is atropine 
during sterilization, which not only hydrolyses in aqueous solution to tropine and 
tropic acid but also dehydrates to form apoatropine during sterilization. 
3. Oxidation 
        The term oxidation is applied to reactions in which either one or more 
electropositive atoms, radicals, or electrons are lost or one or more electronegative 
atoms or radicals are gained.  
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4. Isomerisation 
          Isomerisation is the conversion of a substance into its geometric or optical 
isomers; these have the same structural formula but differ in stereochemical 
configuration. 
5. Polymerization 
         The combination of two or more identical molecules of a substance to form a 
more complex molecule is known as polymerization.  
6. Photochemical Reactions 
        When exposed to light many drugs and excipients are susceptible to degradation 
by a variety of photochemical reactions. 
1.4.3 Chemical kinetics 
         Chemical kinetics is concerned with the rate and mechanism of chemical 
reactions. Application of the theory of chemical kinetics enables the rate of 
degradation of a drug substance or excipients to be calculated from the results of 
stability experiments conducted under specified conditions. Useful information can be 
obtained on the nature and number of intermediate steps in a degradation reaction and 
on the effects of factors such as concentration of reactants, temperature, pH and 
surfactants 
1.4.3.1   Rate Expression 
         The theory of chemical kinetics is based upon the law of mass action. In 
accordance with this law, the rate of chemical change in a reaction varies directly as 
the active molar concentrations of the reacting substances.  
mA+ nB? Products 
In which the active concentration of A and B are equal to their actual concentration in 
the system, the rate of reaction is expressed as: 
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- d [A]/dt = k[A]m[B]n 
This mathematical equation is known as the rate expression or general rate equation. 
The proportionality constant k is the rate constant for the reaction. Since the 
concentration of the reactants [A] and [B] decrease as the reaction progress, the rate 
of reaction must decrease with time. Thus the rate constant is more convenient and 
useful than is the rate of reaction at a particular time as a measure of the progress of 
the reaction with time. 
1.4.3.2 Order of Reaction 
        The sum of the exponents of the concentration terms in the rate expression is 
known as the order of reaction. In the example given above the exponent of [A] is m 
and that of [B] is n. The overall order of reaction is the sum of the exponents of [A] 
and [B], that is m+n; thus the overall reaction is said to follow (m+n)-order kinetics. 
The order of reaction can also be described as m-order in respect of [A] and n-order in 
respect of [B]. 
1.4.3.2.1  Zero- order Reactions 
In a zero-order reaction the rate is constant and is independent on the concentrations 
of any of the reactants. 
1.4.3.2.2  First-order reactions 
In a first-order reaction the rate is proportional to the concentration of one of the 
reactants.  
K =  2.303/t  log a/(a-x) 
Where: 
a = initial concentration.                  x= amount degraded  
By rearrangement  
log (a-x) = log a – kt/2.303 
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Thus a graph of the logarithm of reactant concentration against time is rectilinear with 
a slope of-k/2.303 and an intercept at t = 0 of log a. The first-order rate constant k can 
be calculated from the regression equation of the straight line. For a first-order 
reaction, k is often expressed as reciprocal seconds. 
t ½ 
The t ½ is calculated similarly: 
t ½  = 2.303/k log a/(a-x) 
t ½ =2.303/k log 1/0.5 
Therefore  
t ½  = 0.693/k 
1.4.3.2.3   Pseudo-first-order reactions 
The term pseudo-first-order reaction is applied where degradation follows first-order 
kinetics although two or more reactant species are involved in the reaction.  
1.4.3.2.4  Second-order Reactions 
In second-order reaction the rate is proportional to the concentrations of the two 
reactants. 
1.4.3.3  Effect of temperature on the Rate constant 
         For most reactions other than photochemical or radiation-induced processes, a 
rise in temperature increases the rate. In many hydrolysis reactions, the rate may 
increase 2 or 3 times for a 10º rise in temperature. 
The effect of temperature on the rate constant of a reaction can be described by the 
Arrhenius equation: 
Kt  =A exp (- Ea/RT) 
Where kit  is the rate constant at a particular thermodynamic (absolute) temperature T 
for the particular rate of reaction . A is Arrhenius frequency factor (or pre-exponential 
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factor) associated with the frequency of collision between the reacting molecules and 
the entropy of reaction ; Ea is the energy of activation that molecules must possess in 
order that collision can lead to reaction; and R is the universal gas constant. For 
application to the stability of drug substances or medicinal products, the Arrhenius 
equation is more usefully expressed in logarithmic form; 
ln k   = ln A –Ea/RT 
log k  = log A – Ea/2.303RT 
Agraph of the logarithm of the rate constant against the reciprocal of temperature is 
rectilinear with a slope of  -Ea/2.303R and an intercept at 1/T = log A.  
The Arrhenius is widely applied to the results of accelerated stability tests on drug 
substances and medicinal products in order to predict the stability at room temperature 
from that at elevated temperatures. 
1.4.3.4   t½ 
        The rate of a chemical reaction can also be expressed as the t50% (tﱢ½ or half-life); 
that is the time taken for one-half of the reactant to degrade. Values for the t50% 
calculated from the results of experiments at elevated temperatures can be used in the 
determination of the order of reaction.  
1.5  Parameters for validation of HPLC methods for drug substance 
and drug products 
 
        Validation of an analytical procedure is defined by the USP as the process by 
which  it is established, by laboratory studies, that the performance characteristic of 
the procedure meets the requirements for the intended analytical applications.  
1.5.1  Typical analytical characteristics : 
A. Accuracy 
      Accuracy is the measure of how close the experimental value is to the true value. 
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Accuracy for a drug in a formulated product, can be performed frequently by the 
addition of known amounts of drug by weight or volume (dissolved in diluent) to the 
placebo formulation, and working in the linear range of detection of the analyte. This 
would be a true recovery for liquid formulations. For formulations such as tablet, 
suppository, transdermal patch, this could mean evaluating potential interaction of the 
active drug with the excipients in the diluent. From a practical standpoint, it is 
difficult to manufacture a single unit with known amount of active drug to evaluate 
recovery. This test evaluates the specificity of the method in the presence of the 
excipients under the chromatographic conditions used for the analysis of the drug 
product.  
        At each recommended level studied, replicate samples are evaluated. The RSD 
of the replicates will provide the analysis variation or how precise the test method is. 
The mean of the replicates, expressed as %label claim, indicates how accurate the test 
method is. 
B.  Precision 
         Precision is the measure of how close the data values are to each other for a 
number of measurements under the same analytical conditions. 
ICH has defined precision to contain three components: repeatability, intermediate 
precision and reproducibility.  
 1. Repeatability is the use of the analytical procedure within a laboratory over a short 
period of time using the same analyst with the same equipment. (USP 31) 
 2. Intermediate precision also known as ruggedness it expresses within-laboratory 
variation or on different days, or with different analyst or equipment within the same 
laboratory. (USP 31) 
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 3. Reproducibility refers to the use of the analytical procedure in different 
laboratories, as in a collaborative study. (USP 31) 
Precision is the measure of the coefficient of variation in % or relative standard 
deviation (RSD), it will determine the variation limit of the analysis. The tighter the 
value, the more precise or sensitive to variation one can expect the results.  
C. Linearity and Range 
         The linearity of an analytical procedure is the ability to elicit test results that are 
directly, or by a well defined mathematical transformation, proportional to the 
concentration of the analyte in samples within a given range. (USP 31) 
Thus linearity is the relationship of concentration and assay measurements. 
Range is defined by USP as the interval between the upper and lower levels of analyte 
that have been demonstrated to be determined with a suitable level of precision, 
accuracy, and linearity using the procedure as written. 
ICH recommends that for establishment of linearity a minimum of five concentrations 
normally be used. 
D. Detection Limit  
        Detection limit is defined as the lowest concentration of analyte in a sample that 
can be detected, but not necessarily quantitated, under the stated experimental 
conditions. ICH  describes a common approach which is to compare measured signals 
from samples with known low concentrations of analyte with those of blank samples. 
Typical signal-to-noise ratios are 2:1 or 3:1. 
E. Quantitation Limit 
         Quantitation limit is the lowest concentration of analyte in a sample that can be 
determined with acceptable precision and accuracy under the stated experimental 
conditions.  
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        ICH describes a common approach which is to compare measured signals from 
samples with known low concentrations of analyte with those of blank samples.  A 
typical signal-to-noise ratio is 10:1.. 
1.5.2  System Suitability Specifications and Tests 
        The accuracy and precision of HPLC data collected begin with a well behaved 
Chromatographic system. The system suitability specifications and tests are parameters 
that provide assistance in achieving this purpose.  
  1. Capacity factor (k') 
    k' = (tR - tO) / tO 
        The capacity factor is a measure of where the peak of interest is located with 
respect to the void volume, i.e., elution time of the non-retained components. 
The peak should be well-resolved from other peaks and the void volume. Generally 
the value of k' from 1 to 10. 
 2. Precision/Injection repeatability (RSD) 
        Injection precision expressed as RSD (relative standard deviation) indicates the 
performance of the HPL chromatograph which includes the plumbing, column, and 
environmental conditions, at the time the samples are analyzed.  
RSD of 1% for n 5 is desirable. 
 3. Relative retention ( ∞) 
    ∞= k'1 / k'2 
         Relative retention is a measure of the relative location of two peaks. This is not 
an essential parameter as long as the resolution (Rs) is stated. 
 4. Resolution (Rs) 
 Rs = (tR2 - tR1) / (1/2) (tW1 + tW2) 
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        Rs is a measure of how well two peaks are separated. For reliable quantitation, 
well-separated peaks are essential for quantitation. This is a very useful parameter if 
potential interference peak(s) may be of concern. The closest potential eluting peak to 
the analyte should be selected. 
        Rs is minimally influenced by the ratio of the two compounds being measured.           
The resolution of peaks is indicated by the Rs values 
 Rs of > 2 between the peak of interest and the closest potential interfering peak, 
(impurity, excipients, degradation product, internal standard, etc.) is desirable. 
 5- Number of Theoretical plates  (N) 
 N = 16 (tR / tW)2 = L / H 
         Theoretical plate number is a measure of column efficiency, that is, how many 
peaks can be located per unit run-time of the chromatogram. N is fairly constant for 
each peak on a chromatogram with a fixed set of operating conditions. H, or HETP, 
the height equivalent of a theoretical plate, measures the column efficiency per unit 
length (L) of the column. Parameters which can affect N or H include peak position, 
particle size in column, flow-rate of mobile phase, column temperature, viscosity of 
mobile phase, and molecular weight of the analyte.  
 Where 
t0 = elution time of the void volume or non-retained components . 
tR = retention time of the analyte 
tW = peak width measured at baseline of the extrapolated straight sides to baseline. 
 
 
 
 
 27
1.6    Total viable aerobic count 
 
         These tests are carried out for the estimation of the number of viable aerobic 
microorganisms present and freedom from designated microbial species in 
pharmaceutical dosage forms from raw materials to the finished products. BP 2003. 
 
1.7 Toxicity studies 
   New medicines or chemicals which may affect the health of humans are required 
by law to be tested on animals. These safety tests, which provide crucial information 
for planning human trials, represent a very small proportion of the development process 
for a new medicine. While animal tests cannot predict all of the reactions a human may 
have to a given substance, broader questions about effects on the heart, liver, lungs or 
skin are answered through animal studies so that its relative toxicity is known.  
          Safety testing begins early in the exploratory development of a potential drug, a 
non-rodent mammalian species, as this gives the minimum data necessary with acute 
toxicity tests. These are usually carried out on a rodent species, and for making 
comparisons between effects on different species. 
1.7.1  Acute toxicity  
         Acute toxicity is the toxicity produced by a pharmaceutical when it is 
administered in one or more doses during a period not exceeding 24 hours. 
Safety tests begin with acute toxicity testing, where the animals are given a single 
high dose of the test compound. The aim of the tests is to determine the range 
between the dose that causes no adverse effect and the dose that is life-threatening. 
Legislative guidance suggests that the effects on test animals should be compared 
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with the effects on control groups of animals which have not received the compound. 
The dose selected for acute toxicity was 15 times of the therapeutic dose. 
The results of these tests allow further studies to be planned, as they give information 
about the dosage that should be used, and how toxicity may occur. 
    1.7.2  Subacute toxicity 
         A compound which survives these early tests can be considered for repeat-dose 
studies in animals. These studies give most of the basic information about how the 
compound acts on the body. The relationship between the dose and the animal’s 
response to the compound is studied in more detail, and the organs that may suffer 
toxic effects are examined.  
        The parameters in this study which included screening on general toxicity 
systems, mortality, body and organ weight, hematology, biochemistry, genotoxicity 
and histopathology were based on standard toxicological screening program (Robin et 
al. 1982; Chan et al. 1982)  
1.7.3 Chronic toxicity studies 
          In order to evaluate the effect of prolonged treatment on the target organs and 
the physiological and metabolic tolerance of the drug product at low doses a period of 
ninety days (WHO scientific group 1967) is suggested to be sufficient in short lived 
rodents, in order to predict hazard of long term low dose exposure of particular drug 
(Mossberg and Hayes 1989). The parameters included in the study were based on the 
standard toxicological screening program (Robin et al. 1982; Chan et al. 1982; 
Mossberg and Hayes 1989) and the findings were substantiated by histopathological 
studies. Once a drug has been studied for long term toxicity in animals, and to 
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determine whether it interacts with DNA to cause mutations, it can be tested on 
humans in phase I clinical trials. 
 
1.8  Objectives: 
         The main objectives of this study is to carry out long term stability studies on 
cat's claw capsules & Devil's claw at different climatic conditions CH1,CH2&CH3 over 
a period of 24 months and toxicity studies including acute, subacute &chronic 
toxicity. The selection of these two herbal drugs was based on the fact that although 
both drugs were registered with the Ministry of Health-Saudi Arabia neither stability 
nor toxicity studies were submitted by the manufacturer. The objectives of the current 
study are: 
1-To study the long term stability of the two drugs in the form of capsules and active 
substances(Isometraphylline &Harpagoside standards) and storing them under 
different simulated climatic conditions for 24 months.  
i-climatic chamber CH1 (25ºC ± 1ºC; RH = 75%) 
ii-Climatic chamber CH2 (30ºC ± 1ºC; RH = 75%) 
iii-Climatic chamber CH3 (35ºC ± 1ºC; RH = 75%) 
2- To study the kinetics for both drugs and calculating the rate constant, half life and 
activation energy for decomposition. . 
3-Development and validation of stability indicating HPLC methods for both drugs in 
the presence of other excipients. 
4- To study the kinetics for both drugs and calculating the rate constant, half life and 
activation energy for decomposition.  
5-To run toxicity studies for both drugs by using male and female mice adopting 
acute, subacute and chronic toxicity modes. The animals were then examined 
regarding body weight changes, the weight of the vital organs, hematological and 
biochemical, histopathological studies. 
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2. Methodology: 
2.1    For Cat's claw 
2.1.1   High performance liquid chromatography: 
         Studies were carried out on isomitraphylline standard and Cat's claw capsules. 
One batch of Cat’s Claw capsules registered and marketed in Saudi Arabia, 
manufactured by Sun Natural, USA having batch number 004013 was selected. The 
active ingredient per capsule is Cat's claw 350 mg. The excipients added in the 
formulation were Magnesium Stearate 12.5 mg/capsule and Maltodextrin 167.5 
mg/capsule, the total weight of capsule was 530 mg. The capsule contains Cat’s claw 
with main active compound isomitraphylline. 
2.1.1.1  Instrument:  
         The HPLC system used comprised of Shimadzu LC-10ADVP pumps, SIL-
10ADVP auto injector, CTO-10ADVP column oven, DGU-14A degasser, SPD-
M10AVP diode array detector and SCL-10AVP system controller.  
A reverse phase C18 Hypersil BDS 4x250 mm 5 µm column was used.  
2.1.1.2.  Materials and Reagents:  
         Acetonitrile, Methanol, HPLC grade purchased from Fischer Scientific (Leister-
U.K), Sodium dihydrogen orthophosphate and Potassium dihydrogen 
orthophosphate: Sigma Aldrich Chemie GmbH, Germany, and Isomitraphylline: 
Chromadex™-U.S.A. 
2.1.1.3.  Mobile Phase:  
        The mobile phase consisted of (A) Acetonitrile and (B) 10 mM phosphate buffer 
freshly prepared as follows:  
         500 ml of 10 mM solution of Sodium dihydrogen orthophosphate was prepared 
by dissolving 0.710 g Sodium dihydrogen orthophosphate in water in a 500 ml 
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volumetric flask and diluted to volume with water. Then 1 L of 10 mM solution of 
Potassium dihydrogen orthophosphate was prepared by dissolving 1.36 g of 
Potassium dihydrogen orthophosphate in water in a 1000 ml volumetric flask and 
diluted to volume with water. 375 ml of the Sodium dihydrogen orthophosphate 
solution was mixed with 625 ml of the Potassium dihydrogen orthophosphate 
solution. The pH was tested with calibrated digital pH meter and adjusted to 6.6 using 
1N H3PO4 to reduce, or 1N NaOH to raise pH.  
Gradient conditions:  
Steps Time program (min) Concentration of B% 
1 0 60 
2 35 40 
3 39 35 
4 40 60 
5 50 60 
Flow rate= 1 ml/min; Wavelength = 245 nm Injection volume= 20 µl  
 
2.1.1.4.   Preparation of the standard stock solution:  
         About 5.3 mg of isomitraphylline standard was weighed in 20 ml volumetric 
flask, dissolved in methanol, sonicated for 5 min, brought to room temperature and 
diluted to volume with methanol.  
2.1.1.5.   Preparation of test sample:  
         20 capsules were emptied and the contents were mixed well. An amount 
equivalent to 500 mg of the capsule content was weighed, dissolved in 10 ml of 
methanol and shaked for one hour. 1 ml of this solution was transferred to a 10 ml 
volumetric flask and completed to volume with methanol.  
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2.1.1.6   Final concentration  
         Both sample and stock standard solution were diluted ten times to get the final 
concentrations to be injected (26.5 µg/ml). 
2.1.2.   Elemental Analysis:  
2.1.2.1.   Instruments:  
         Shimadzu AA-6800 Atomic absorption spectrophotometer with graphite and 
flame auto switch over mode, ASC 6100 auto sampler and HVG1 hydride generator 
was used. The amount of each element was determined by using appropriate lamp. 
The content of the respective element was calculated by using a calibration graph.   
Range of wavelengths: 190 to 900 nm. 
Microwave Digestion system and Teflon Digestion System.  
 Furnace: Programmable, or muffle furnace with thermostat maintaining 450 ± 25°C.   
 Polystyrene bottles: With leak-proof closures, 100 ml. 
Carefully cleaned and rinsed glassware and plastic ware with HNO3 or HCl to avoid 
metal contamination.   
2.1.2.2.   Materials and Reagents: 
         Unless otherwise specified all the reagents were AR grade, deionized water was 
used throughout the study.  
6M Hydrochloric acid: 500 ml HCl (37% w/w), diluted with deionized water to 1L 
Nitric acid (65% (w/w).0.1M HNO3: 7 ml HNO3 65% (w/w), diluted with deionized 
water to 1 L. 
30% Hydrogen peroxide: 30 ml from Conc. Hydrogen peroxide completed to 100 ml 
with deionized water. 
Diluent: Prepared by taking 1 ml of Conc. Nitric acid and completed to 1 liter with 
deionized water.  
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2.1.2.3.   Preparation of the elements standard stock solutions:  
         Lead standard solution (1mg/ml), mercury standard solution (1mg/ml), arsenic  
standard solution (1mg/ml), sodium standard solution (1mg/ml), calcium standard 
solution (1mg/ml), chromium standard solution (1mg/ml), cadmium standard solution 
(1mg/ml), potassium standard solution (1mg/ml), magnesium standard solution 
(1mg/ml), copper standard solution (1mg/ml), manganese standard solution (1mg/ml) 
and iron standard solution (1mg/ml) all obtained from Sigma-Aldrich Chemie GmbH, 
Germany were used to prepare the standard solutions.  
2.1.2.4.   Preparation of the working standard solution: 
        For graphite furnace analysis: Standard solutions, were diluted with 0.1M 
HNO3 to a range of standards that covers the linear range of the element to be 
determined.  
         For flame analysis: standards were diluted with 0.1M HNO3 to a range of 
standards that covers the concentration of the element to be determined. 
2.1.2.5. Preparation of test sample: 
Solid sample preparation:  
        Drying: In a crucible, 1 g of the sample was weighed and transferred to a drying 
oven. 
        Ashing: Ashing was done in a programmable furnace. The dish was placed in 
furnace at initial temperature not exceeding 100°C. Temperature was increased at a 
maximum rate of 50°C/h to 450°C. The dish was kept overnight in the oven. The 
crucible was taken out of furnace and cooled to room temperature. The ash was 
moistened with 3 ml water and evaporated on hot plate. The crucible was returned 
back in furnace at a maximum of 200°C and temperature was raised (50-100°C/h) to 
450°C. Ashing was proceeded at 450°C for 1-2 h. The procedure was repeated until 
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product is completely ashed. 5 ml of 6M HCl was added to crucible ensuring that all 
ash comes into contact with acid. The acid was evaporated on water-bath. The residue 
was dissolved in 30 ml, to the nearest 0.1 ml, of 0.1M HNO3. The crucible was 
swirled with care so that all ash came into contact with acid, covered with watch glass 
and let to stand for 1-2 h. The solution was stirred in crucible thoroughly with stirring 
rod and the contents transferred to plastic bottle. Two blanks were included with each 
analytical batch. The blanks were treated in the same way as products.  
Background correction was always used in flameless AAS and for flame applications 
at low concentrations. 
When results were outside of the linear range, the test solutions used were diluted 
with 0.1M HNO3. 
Graphite furnace (flameless) and Hydride furnace technique: Were used and 
measurements were made with peak area rather than peak height. 
2.1.2.6.  Calculations and Evaluation of Results: 
Detection limit: The detection limit for each metal was calculated as follows:  
Detection limit = 3 × standard deviation of the mean of the blank determinations 
(n≥20) 
The concentration C of metal in the test sample was calculated according to the 
formula: 
m
V x b)-(aC =
 
Where C = concentration in the test sample (mg/kg) 
a = concentration in the test solutions (mg/L) 
b = mean concentration in the blank solutions (mg/L) 
V = volume of the test solution (ml) 
m = weight of the test portion (g). 
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If (a-b) is lower than the detection limit, then (a-b) is substituted with 
detection limit for calculation of the limit of detection in the test portion. 
If test solution has been diluted, dilution factor has to be taken into account. 
When running triplicates, the average of the results should be given within 
3 significant figures. 
         The contents of each element were calculated by using a previously plotted 
calibration graph and each injection for the different elements was repeated three 
times. 
2.1.3.   Stability Studies: 
          Cat’s claw capsules were stored under different simulated climatic conditions: 
Climatic chamber No. 1 (25°C ± 1°C, humidity: 75%); Climatic chamber No. 2 (30°C 
± 1°C, humidity: 75%) and Climatic chamber No. 3 (35°C ± 1°C, humidity 75%), for 
24 months and each six months analysis was carried out. The rate constant, half life 
and activation energy for the decomposition were calculated.  
2.1.3.1   Physical Examinations: 
         Cat’s claw capsules were stored at different temperature settings ranging from 
25°C, 30°C and 35°C with 75% humidity for different time intervals up to 24 months. 
The capsules were inspected regarding shape, odor and colour. 
2.1.3.2   Microbiological Studies: 
         The drug sample was tested using the standard protocol for the total viable 
aerobic count of bacteria and fungi to check the possible presence of Escherichia coli; 
Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella.  
2.1.3.2.1   Preparation of sample 
        About 10 g of the sample was suspended in 100 ml buffered sodium chloride-
peptone solution pH 7.0.  
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2.1.3.2.2    Examination of the sample 
        The examination is carried out using Pour Plate Method in which 1 ml of the 
prepared sample is added to 15 ml of liquefied  Soyabean-Casein Digest agar suitable 
for bacteria and 1 ml of the prepared sample is added to 15 ml of liquefied Sabouraud 
Dextrose agar suitable for fungi. The plates were then incubated at 30-35º for bacteria 
and 20-25ºC for fungi for 5 days. 
        The arithmetic average of the counts was taken and the number of colony-
forming units per gram (cfu) were calculated.  
2.1.4.   Toxicity Studies: 
2.1.4.1  Materials: 
         Ether, Haematoxylin, Eosin, Formalin, Methanol (Sigma-Aldrich). Test 
combination reagents (Boehringer MannheimGmbH,Diagnostica-Germany).  
2.1.4.2 Instruments: 
        Coulter counter, Spectrphotometer, Introspect II (LKB). American optical Rotary 
Microtome, Optical microscope, centrifuge. 
2.1.4.3  Toxicity tests: 
        Toxicity studies were conducted using male and female mice adopting acute, 
subacute and chronic modes. The animals were examined regarding body weight 
changes and at the end of the treatment, the weight of the vital organs and conditions 
of the viscera were compared to normal and control animals. Histopathological, 
hematological and biochemical studies were also conducted as follows:  
Animal Stock: In each case for the toxicity evaluation Swiss albino mice aged 6-7 
weeks and weighing 20-25 g (home breed) were used. The animals were maintained 
under standard conditions of humidity, temperature and light (12 h dark / 12 h light). 
The animals were fed with Purina chow diet and free access to water.  
        Unless otherwise specified the following parameters were studied in acute, sub-
acute and chronic toxicity evaluation.  
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General toxicity symptoms: The general toxic symptoms were observed within 24 hrs 
for acute and sub-acute studies while these observations were continued for two 
weeks for chronic study. The observations were allowed sufficient time for the onset 
of signs, recovery and the time of death. The different toxic symptoms observed were 
autonomic responses, motor activity and CNS excitation, etc. (Chan et al. 1982).  
Incidence of mortality: In sub-acute and chronic toxicity studies, the animals were 
observed for mortality daily and at the end of the treatment to analyze the impact of 
the treatment.  
Body weight: The body weight of individual animals was taken before the beginning 
of the treatment and at the end of the treatment. The difference was computed 
statistically to examine the impact of the different drugs on body weight. 
Organ weight: At the end of the treatment the vital organs viz., heart, lungs, kidney, 
spleen, liver and testis were weighed and computed on a per 100 gm body weight 
basis.  
Blood Collection: The animals were anesthetized with ether and blood was taken 
from the heart by direct puncture.  
Hematology: The blood was analyzed on a coulter counter for the quantification of 
different hematological indices, such as WBC, RBC, hemoglobin, haematocrit and 
MCV.  
Biochemical indices: The blood was collected, serum samples were separated, stored 
at -20ºC and analyzed for alanine aminotrasnferase (ALT/GPT), aspartate 
aminostrasnferase (AST/GOT), alkaline phosphatase, enzyme MB of creatine kinase 
(CK-MB), glucose, urea and creatinine. The parameters were analyzed by an 
enzymatic colorimetric method using test combination reagents (Boehringer 
 38
Mannheim GmbH, Diagnostica, Germany). The measurements were carried out in a 
spectrophotometer, Introspect II (LKB).  
Genotoxic studies: The adhering soft tissue and epiphyses of both the tibiae were 
removed. The marrow was aspirated from each femur in fetal calf serum and 
transferred to centrifuge tubes. After centrifugation at 1000 rpm for 5 min. the 
supernatant was discarded and the residual cells were spread on slides and air dried. 
The slides were fixed in methanol, stained in May-Gruenwald solution followed by 
Giemsa stain. The coded slides were screened for the presence of micronuclei in 
polychromatic erythrocytes which indicated non-disjunction, chromosomal breaks and 
structural or numerical changes in the chromosomes. The bone marrow depression 
(mitotic index) was evaluated on the basis of the ratio of polychromatic to 
normochromatic erythrocytes (PCE/NCE ratio) (Al-Harbi et al. 1994).  
Histopathological procedures: Tissue samples of liver, heart and kidney were 
preserved in 10% buffered formalin and processed for routine paraffin block 
preparation. Using an American Optical Rotary Microtome, sections of thickness 
about 5 µm were cut and stained with haematoxylin and eosin. These were examined 
under the microscope for the following histopathological changes:  
Liver: Abnormal portal spaces, abnormal duplication of kupffer cells, changes in the 
number of binuclear cells, abnormal medullary erythropoiesis, presence of 
megakaryocytes, mitotic division, lymphocytic infiltration, necrosis and congestion.  
Heart: Inflammatory changes, lymphocytes, necrosis and congestion.  
Kidney: Abnormal peripheral fats, abnormal cellularity, abnormal glomeruli, 
abnormal cortex, abnormal medulla, congestion, necrosis. (Al-Harbi et al. 1995). 
 In chronic toxicity studies in addition lungs and spleen were also investigated for 
histopathological changes. The microphotographs of the chronic studies are included.  
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Statistical analyses: For the evaluation of results obtained during acute, sub-acute and 
chronic toxicity studies: Student's t-test and Chi-square test were used to assess the 
significance of the values obtained in the treated groups as compared to controls.  
Acute toxicity evaluation: The dose selected for acute toxicity was 15 times of the 
therapeutic dose (150mg/kg). The drug in each case was suspended separately and 
homogenously (in 1% carboxymethyl cellulose solution (CMC) and administered 
orally (0.5 ml per mouse) in a single acute dose. The control group received equal 
amount of vehicle. The animals were observed for seven days after treatment. Each 
control and treatment groups contained randomly allotted 10 male and 10 female mice 
kept separately. The animals were observed for any sign of toxicity.  
Sub-acute toxicity evaluation:  The study on sub-acute treatment involves repeated 
dose exposures for short term and it is recommended to provide information on 
cumulative effects, latency period for development of toxicity, reversibility of toxicity 
and dose response relationship (OECD 1981; Chan et al. 1982). The parameters 
included in this study were based on standard toxicological screening program (Robin 
et al. 1982; Chan et al. 1982) and included screening on general toxicity systems, 
mortality, body and organ weight, hematology, biochemistry, genotoxicity and 
histopathology.  
Dose selection and route of administration: During sub-acute treatment study 
treatment of different animal groups was done with a dose which was 5 times more 
than the recommended therapeutic dose (50 mg/kg). All male and female treatment 
groups were given the drug orally (suspended in 1% carboxymethyl cellulose 
solution) every other day for seven days. The control groups received vehicle in the 
same dose (0.5 ml).  
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Chronic toxicity evaluation: For chronic toxicity test the prolonged treatment for a 
period of ninety days (WHO scientific group 1967) is suggested to be sufficient in 
short lived rodents, in order to predict hazard of long term low dose exposure of 
particular drug (Mossberg and Hayes 1989). The purpose of this investigation was to 
evaluate the effect of prolonged treatment on the target organs and the physiological 
and metabolic tolerance of the drug product at low doses. The parameters included in 
the study were based on the standard toxicological screening program (Robin et al. 
1982; Chan et al. 1982; Mossberg and Hayes 1989) and the findings were 
substantiated by histopathological studies.  
Dose solution and route of administration: The regulatory guidelines on selection of 
dose for long term treatment require minimal toxicity to allow meaningful evaluation 
of data (Mossberg and Hayes 1989). The doses selected for each drug were in the 
range of human therapeutic dose (10 mg/kg/day) (Mossberg and Hayes 1989). Mice 
were randomly allotted to different control and treatment groups (10 male and 10 
female mice in each group). The animals used aged 6-7 week and having weight 19-
22 gm. All animals were kept under standard conditions and treatment was given in 
drinking water. The treatment was continued for three months. As body weight and 
water intake increase by time, the daily dose was adjusted daily to be equal to the 
initial human therapeutic dose specified by the manufacturer. 
Adriamycin treatment: An established cytotoxic drug 'Adriamycin' was used as a 
reference. Adriamycin was injected (i.p.) in a single dose of 8mg/kg body weight to 
the animals 30 hours before sacrifice.  
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2.2       For Devil's claw 
2.2.1.   High performance liquid chromatography: 
      Studies were carried out on harpagoside standard and Devil's claw capsules. One 
batch registered and marketed in Saudi Arabia of Devil's claw capsules,  
manufactured by Bioron, France having batch number 003010B was chosen. The 
active ingredient per capsule in Devil's claw is 189 mg. The excipients added in the 
formulation are magnesium stearate 5 mg/capsule, precipitated silica (5 µm) 8 
mg/capsule and precipitated silica (3-4 µm) 2 mg/capsule. The total weight of 
capsule is 204 mg. The capsule contains Devil's claw with main active compound 
harpagoside. 
2.2.1.1.  Instrument:  
         The HPLC system used comprised of Shimadzu LC-10ADVP pumps, SIL-
10ADVP auto injector, CTO-10ADVP column oven, DGU-14A degasser, SPD-
M10AVP diode array detector and SCL-10AVP system controller.  
2.2.1.2.  Materials and Reagents:  
        Methanol: HPLC grade; purchased from Fiscer Scientific(Leister-U.K),Water: 
Purified water; Harpagoside: Chromadex™ U.S.A. 
2.2.1.3. Mobile Phase:  
        The mobile phase consisted of a mixture of 40 volumes of water and 60 volumes 
of methanol.  
         Flow rate: 1ml / min; Wavelength: 278 nm; Injection volume: 20 µl; Oven 
temperature: 30ºC 
2.2.1.4.   Preparation of the standard stock solution:  
        About 20 mg of harpagoside standard was dissolved in methanol and completed 
to 100 ml with the same solvent.  
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2.2.1.5.   Preparation of test sample:  
        20 capsules were emptied and the average weight was determined. To 1.0 g of 
the capsule contents, 90 ml of methanol was added. The mixture was stirred with a 
magnetic stirrer for one hour and completed to 100 ml with the same solvent. Then it 
was filtered through 0.2 µm filter. 
2.2.1.6.   Final concentration:  
        Both sample and stock standard solution were diluted five times to get the final 
concentrations to be injected (40µg/ml). 
2.2.2.   Elemental Analysis:  
2.2.2.1.   Instruments:  
        The instruments used are the same as mentioned under elemental analysis for 
Cat's claw refer to 2.1.2.1. 
2.2.2.2.   Materials and Reagents: 
        The same as mentioned under materials and reagents for Cat's claw refer to 
2.1.2.2. 
Preparation of the standard stock solution:  
The same as mentioned under materials and reagents for Cat's claw refer to 
2.1.2.3.  
2.2.2.3.  Preparation of the working standard solution: 
         Refer to 2.1.2.4 under Cat's claw. 
2.2.2.4. Preparation of test sample: 
Solid sample preparation: 
       The same as mentioned under Cat's claw refer to 2.1.2.5.  
2.2.2.5.   Calculations and Evaluation of Results: 
        The same as mentioned under Cat's claw refer to 2.1.2.6.  
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2.2.3.   Stability Studies: 
        Devil's claw capsules were stored under different simulated climatic conditions: 
climatic chamber No. 1 (25°C ± 1°C, humidity: 75%), climatic chamber No. 2 (30°C 
± 1°C, humidity: 75%) and climatic chamber No. 3 (35°C ± 1°C, humidity 75%). The 
rate constant, half life and activation energy for the decomposition were calculated.  
2.2.3.1  Physical Examinations: 
        Devil's claw capsules were stored at different temperature settings ranging from 
25°C, 30°C and 35°C with 75% humidity for different time intervals up to 24 months. 
The capsules were inspected regarding shape, odour and color. 
2.2.4  Microbiological Studies: 
         Refer to 2.1.3.2 under Cat's claw. 
2.2.4.1  Preparation of test sample: 
        Refer to 2.1.3.2.1 under Cat's claw. 
2.2.4.1 Examination of test sample: 
        Refer to 2.1.3.2.2 under Cat's claw. 
2.2.5  Toxicity Studies: 
2.2.5.1   Materials: 
        The same as mentioned under Cat's claw refer to 2.1.4.1. 
2.2.5.2   Instruments: 
        The same as mentioned under Cat's claw refer to 2.1.4.2. 
2.2.5.3  Toxicity tests: 
        The same as mentioned under Cat's claw refer to 2.1.4.3. 
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3.   Results and Discussion:  
 
3.1  For Cat's claw  
 
 
 
 
 
 
 
 
 
 
 
Figure1.1:  A typical HPLC chromatogram of Isomitraphylline standard.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.2:  A typical HPLC chromatogram of the contents of Cat's claw capsules. 
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3.1.1   Method validation:  
         Method validation establishes that the method performance characteristics are 
suitable for the intended use. Validation entails evaluation of various parameters of 
the method such as selectivity, accuracy, precision, linearity (concentration-detector 
response relationship) sensitivity, detection and quantitation limits and recovery 
percentage were studied.    
3.1.1.1   System suitability:  
        The reported method was adopted to follow isomitraphylline standard and good 
separation for active ingredients in Cat's claw capsules and other compounds (Figures 
1.1-1.2). This method can thus be considered a stability indicating one. Number of 
theoretical plates, capacity factor, resolution, asymmetry, width at 5% height, and 
United States Pharmacopoeia (USP) width are collected in Table 1.2.  
Table1.2:  System suitability parameters.  
RT 
Theoretical 
plates 
Capacity 
factor K 
Resolution Asymmetry
USP 
width 
Width at 
5% height 
25.26 25205 12.13 4.42 1.22 0.63 0.36 
 
3.1.1.2   Selectivity:  
         For chromatographic methods specificity is the ability of the method to 
accurately measure the analyte response in presence of all potential sample 
components. The selectivity criterion for an assay method is that analyte peaks with 
suitable resolution from all other sample components (see Figures1.1-1.2).  
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3.1.1.3.  Linearity:  
        The calibration graph was prepared by plotting the peak area of standard 
isometraphylline (Figure1.3), from which the following regression equation was 
derived. y = 0.0452 x + 0.0025- - - - - - - - - - - - - - - -  - R2 = 0.9998 
Where y = Peak area and x = Concentration in µg/ml.  
For testing the linearity the following solutions were prepared (Table 1.3).  
Table1.3: Standard solutions for testing linearity.  
S. No. Concentration in µg/ml. Peak area of isometraphylline standard. 
1. 10 0.453*106 
2. 15 0.679*106 
3. 20 0.919*106 
4. 25 1.123*106 
5. 30 1.359*106 
6. 35 1.595*106 
7. 40 1.788*106 
8. 45 2.039*106 
9. 50 2.266*106 
 
 
 
 
 
 
 
 
 
 
Figure1.3:  The Calibration curve of Isomitraphylline using HPLC method. 
3.1.14  Precision:  
        The validity of the method was proved by analyzing six injections of 
isomitraphylline (concentration 30 µg/ml). The percentage recovery was found to be 
100.06± 0.51% (Table 1.4).  
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Table1.4 Results of the six injections from the standard of isomitraphylline (30 
µg/ml). 
S. No. Calculated concentration (µg/ml) Recovery % 
1. 30.070 100.23 
2. 30.120 100.40 
3. 29.870 99.57 
4. 30.230 100.80 
5. 29.980 99.93 
6. 29.830 99.43 
Average 30.017 100.056 
RSD%  0.51 
 
 
3.1.1.5.  Accuracy and Recovery:  
        The accuracy of the method was proved by analyzing six replicate of different 
concentration of isomitraphylline over the lower concentration 2.35 µg/ml and higher 
concentration 136.5 µg/ml. Each injection replicate (three times) the percentage 
recovery was calculated according to Cuadros et al. (1995). In our case the recovery 
was found 99.71±0.99% for lower concentration and 100.001±0.185% for higher 
concentration (Table1.5).  
Table1.5: Results of six injections of two concentrations for the accuracy 
determination.  
S. No. Concentration 2.35 µg/ml 
Recovery 
% S. No. 
Concentration 
136.5 µg/ml 
Recovery 
% 
1. 2.33 99.15 1 136.10 99.70 
2. 2.31 98.30 2. 136.32 99.87 
3. 2.37 100.85 3. 136.60 100.07 
4. 2.33 99.15 4. 136.76 100.19 
5. 2.36 100.43 5. 136.72 100.16 
6. 2.36 100.43 6. 136.51 100.01 
Average 2.34 99.71 Average 136.50 100.001 
RSD %  0.99 
 
RSD %  0.185 
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3.1.1.6.  Limit of detection and quantitation:  
        The detection limit (LOD) of a method is the lowest analyte concentration that 
produces response detection above the noise level of system, typically taken as three 
times the noise level. The quantitation limit (LOQ) is the lower level of analyte that 
can be accurately measured, and it is often evaluated as ten times the noise level. Both 
detection and quantitation limits need to be determined only for impurity methods. In 
our case, the proposed method is for the assay of isomitraphylline in Cat's claw 
capsules, we have evaluated both quantities according to the procedure of Miller and 
Miller (1988) calculated as three and ten times, respectively.  
       The minimum concentration at which isomitraphylline could reliably be detected 
or quantified was established by measured signals from samples with those of blank 
(Methanol). According to the described conditions the sensitivity results were:  
Limit of detection (LOD)   = 0.4 µg/ml 
Limit of quantification (LOQ)  = 1.0 µg/ml  
3.1.2. Effect of Temperature: 
        The effect of rise of temperature on the rate of reaction is given by Arrhenius 
Law which shows an exponential relation between the rate constant (K) and 
temperature (Keaneth, et al. 1984; Martin 1993).  K = Ae− Ea/RT 
Where K stands for the rate constant, Ea is the activation energy, R is the universal 
gas constant (1.98 Cal/mol-degree), Ae is the exponential and T is the absolute 
temperature.  
        All kinetic experiments were performed at controlled temperature at t±1oC where 
t=25, 30, 35oC with 75% humidity. All reactions, were run under pseudo- first order 
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conditions with catalyst in excess. The apparent rate constants were obtained from the 
slopes of semi logarithmic linear plots using the least squares method.   
         Cat's claw capsules and isomitraphylline standards were stored under different 
simulated climatic conditions:  
1. Climatic chamber CH1 (25ºC ± 1ºC; RH = 75%) 
2. Climatic chamber CH2 (30ºC ± 1ºC; RH = 75%) 
3. Climatic chamber CH3 (35ºC ± 1ºC; RH = 75%) 
  The samples were studied for 24 months. Samples from different conditions were 
studied every six months and subjected to different analysis.  
        Assay of isomitraphylline standard and in Cat's claw capsules was made at 
different time intervals and conditions according to the developed and validated 
HPLC method. The concentration of isomitraphylline was followed by injecting 20 
µl. The concentration of intact isomitraphylline was calculated from the standard 
curve plotted as peak area of standard isomitraphylline versus the concentration 
(Figure 1.3).  
Table 1.6: %w/v of isomitraphylline in Cat's claw capsules at different time intervals 
and temperature.  
Time /month CH 1 % CH 2 % CH 3 % 
0 100 100 100 
6 99.43 99.14 99.01 
12 99.23 98.52 97.85 
18 99.03 98.06 97.28 
24 98.92 97.47 96.06 
 
 
Table 1.7: %w/v of isomitraphylline reference material at different time intervals and 
temperatures.  
Time /month CH 1 % CH 2 % CH 3 % 
0 100 100 100 
6 97.28 96.48 93.86 
12 94.34 91.85 87.87 
18 92.66 88.26 82.37 
24 90.95 85.18 76.57 
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From table (1.6 ) it is clear that isomitraphylline in Cat's Claw capsules is stable over 
the range of 25ºC, 30ºC and 35ºC with humidity 75%. Isomitraphylline in Cat's Claw 
capsules undergoes slight decomposition and it loses about 0.57%, 0.86% and 0.99% 
for six months at CH1, CH2 and CH3, respectively. The rate of decomposition 
increases more and it loses around 1.08%, 2.53% and 3.94% after 24 months at CH1, 
CH2 and CH3 respectively.   
From table (1.7) it is clear that the isomitraphylline standard is unstable over the range 
of 25ºC, 30ºC and 35ºC with humidity 75%. Isomitraphylline undergoes slight 
decomposition and it loses about 2.72%, 3.52% and 6.14% for six months at CH1, 
CH2 and CH3, respectively. The rate of decomposition increases more and it loses 
around 9.05% and 14.82% and 23.43% after 24 months at CH1, CH2 and CH3 
respectively. On comparing isomitraphylline as standard and in the form of capsules it 
was clear that isomitraphylline standard was found to be less stable than 
isomitraphylline in capsules, as the capsule shell protected isomitraphylline from 
decomposition. The kinetic parameters for the degradation of isomitraphylline at 
different temperatures 25ºC, 30ºC and 35ºC with humidity 75% were found to be 
first-order condition. The semi-logarithmic plot of  log (a/a-x) against time (t) were 
found to be straight line with a slope of 0.0017, 0.0030 and 0.0048 for CH1, CH2 and 
CH3 samples, respectively as shown in Figure 1.5 using the formula for the first-order 
reaction kinetics
xa
a
−= log2.303
kt
. 
       The reaction rate constant (K) was found to be 0.0039, 0.0069 and 0.0111 month-
1 for CH1, CH2 and CH3 samples respectively. The half life time t1/2 was obtained 
from the following formula: 
k
693.0t1/2 =  and was found to be 177, 100.3 and 62.7 
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month for CH1, CH2 and CH3 respectively. The activation energy (Ea) was obtained 
from the following formula: 
2 1TTR303.2
)12( 
k1
k2 log TTEa −= . 
The average activation energy was also calculated and was found to be 18.6 
kcal/mole. The average of this value lies within typical range of 10-30 Kcal/mole 
estimated for hydrolysis reactions (Fung L.H et al 1990). An ester and amide 
functional groups are present in Isomitraphylline molecule. Due to adverse storage 
conditions and high temperature such functional groups may lead to degradation 
(Keaneth et al. 1984). All these results are collected in Table 1.8.  
Systemic studies were carried out at several degrees, usually in the range 25°C, 30°C 
and 35°C with 75 % humidity (Figure1.5) and showed the effect of temperature on the 
degradation of isomitraphylline over the range 25°C, 30°C and 35°C with 75 % 
humidity. The rate constant at each temperature was determined from a suitable plot, 
and Log K was plotted against the reciprocal of temperature (1/T). From the slope of 
such plots, the activation energy was calculated as shown in Figure 1.4. The 
magnitude of the activation energy measures the energy barrier separating reactants 
from products. The smaller the value of the activation energy, the easier is the 
crossing of the energy barrier, and hence the occurrence of the reaction is more likely. 
The reaction rate constant was calculated at each temperature and the activation 
energy was calculated from the following relation: 
                                                
21
12
1
2
303.2
)(
TRT
TTE
K
KLog a −=  
Where K2 and K1 are the rate constants at T2 and T1, respectively. 
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Figure 1.4: Arrhenius plot for isomitraphylline standard at different temperatures 
 
 
Table 1.8: Effect of temperature on the kinetic parameters of isomitraphylline 
Temp. °C Slope K(month−1) log K t½(month) Ea (Kcal / Mole) 
CH1 0.0017 0.0039 −2.4 177 
CH2 0.0030 0.0069 −2.16 100.3 
CH3 0.0048 0.0111 −1.96 62.7 
  
 
 
 Average activation energy       18.6 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Stability studies on Isomitraphylline exposed to different simulated                           
climatic conditions 
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3.1.3. Elemental Analysis:  
         Cat's claw was found to contain sodium, relatively large amount of magnesium, 
potassium and calcium. No other element especially heavy metals were found (Table 
1.9).  
Table1.9:  Elemental analysis results of Cat's claw.  
 Element Results (µg/g) Element Results (µg/g) 
Sodium 769 Potassium 4192 
Calcium 8877 Magnesium 1958 
Iron NF Copper NF 
Chromium NF Manganese NF 
Lead NF Mercury NF 
Cadmium NF Arsenic NF 
NF = Not found.  
 
Table1.10  Validation of Elemental analysis by Atomic Absorption. 
 Slope 
Range of 
standards 
µg/ml 
Correlation 
Factor LOD 
A.A 
technique 
Sodium 0.4275 0.2-0.6 0.99 0.06  ppm Flame 
Calcium 0.065 2-6 0.99 0.06 ppm Flame 
Iron 0.045 0.1-0.3 0.98 0.01ppm Flame 
Chromium 0.013 25-75 0.99 1.00 ppb Flameless 
Lead 0.0004 10-30 0.99 2.00 ppb Flameless 
Cadmium 0.15 0.2-0.6 0.99 0.1 ppb Flameless 
Potassium 0.27 0.05-0.15 0.99 0.05 ppm Flame 
Magnesium 0.9225 0.2-0.6 0.99 0.02 ppm Flame 
Copper 0.07 0.1-0.3 0.99 0.01 ppm Flame 
Manganese 0.12 0.1-0.3 0.99 0.01 ppm Flame 
Arsenic 0.0045 2-6 0.99 0.2 ppb HVG 
Mercury 0.0038 10-30 0.99 1.00 ppm HVG 
 
The accuracy of the method was proved by analyzing three replicate of different 
concentration of elements. 
 
3.1.4.  Physical examination:  
        The Cat's claw powder and shell were examined over the period of 24 months. 
The powder retained its brown color and no distinctive odor was noticed except that 
after 24 months under CH3 condition the capsule content became dark brown powder. 
Similarly, the capsule shell remained transparent and colorless over the same period 
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except in CH2 and CH3 conditions after 24 months the capsule contents become like 
hard cylindrical lumps.  
3.1.5. Microbiological studies:  
        The drug samples were tested using standard protocol for the total viable count 
for bacteria, fungi, Escherichia coli, Staphylococcus Aureus, Pseudomonas 
aeruginosa and salmonella. The results are presented as follows (Table1.11). 
 
Table 1.11: Microbiological counting on Cat's claw capsules stored at different 
climatic chambers. 
‘Microbial counts − Cat’s claw capsules’ (Storage Location) 
CH 1 CH 2 CH 3 Duration (Month)  
B  F B  F  B F 
Zero time  <10 <10 <10 <10 <10 <10 
6  <10 <10 <10 <10 <10 <10 
12 <10 <10 <10 <10 <10 <10 
18  <10 <10  <10 <10  <10 <10 
24 <10 <10 <10  <10 <10 <10 
CH1: Climatic Chamber No. 1 (25°C±1°C-humidity 75%). 
CH2: Climatic Chamber No. 2 (30°C ± 1°C-humidity 75%). 
CH3: Climatic Chamber No. 3 (35°C ± 1°C-humidity 75%). 
B: Total viable count of aerobic bacteria in colony forming unit/gm. 
F: Total viable count of fungi in colony forming unit/gm. 
 
        The results of the microbiological studies revealed no significant changes in total 
viable aerobic count of bacteria and fungi. As shown in the Table 1.11 the total count 
of viable aerobic bacteria and fungi was less than 10 cfu, regardless of storage 
conditions. These results clearly demonstrate the microbiological stability of Cat's 
claw capsules. The results also indicate that the primary pathogens Escherichia coli, 
Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella were not present in 
all the tested samples of Cat's claw capsule. 
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3.1.6.  Toxicity Studies:  
         The result of acute toxicity studies in mice demonstrated that there was 
statistically non significant gain in body weight of animals in the treated and control 
groups (Table 1.12). Among the vital organs there was slight increase in the liver 
weight and kidney in male mice while there was no such change in other organs of 
treated male and female mice in the treatment groups (Tables 1.13-1.14). 
Histopathological investigations confirmed all the vital organs studied to be normal 
and comparable to the control. Hematological studies revealed a significant reduction 
in WBC levels (P< 0.05) of treated male and female mice. There was also a moderate 
increase in the platelet count of treated male mice. Other hematological parameters 
for both the treated female and male animals remained comparable to those of the 
control without any significant changes (Tables 1.15-1.16). Biochemical parameters 
for control and treatment groups showed statistically significant changes. There was 
statistically significant increase (P<0.05) in urea, AST and ALT levels of Cat’s claw 
treatment in male and female mice as compared to the control (Tables 1.17-1.18). The 
noticeable differences observed during acute toxicity studies were considered 
appropriate to be confirmed by conducting sub-acute toxicity experiment. Clastogenic 
effects for control and treatment groups showed statistically non-significant changes 
(Table 1.19).  
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Table 1.12: Quantitative data on body weight changes in mice after acute treatment 
(150 mg/kg) with Cat’s claw.  
Male (g) Female (g) Treatment 
Group Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Control 22.81 ± 0.61 23.50 ± 0.85 20.25 ± 1.05 21.34 ± 0.55 
Cat’s claw  21.23 ± 0.55 22.44 ± 0.65 20.28 ± 0.93 21.35 ± 0.74 
P > 0.05 (Student’s t-test). All results are expressed as: Average body weight ± S.E.  
Pre-treatment body weight was compared with post-treatment body weight.  
10 male and 10 female mice were used in each group. 
 
 
 
Table 1.13: Quantitative data on the average weight of selected organs of male mice 
(per 100 g body weight) after acute treatment (150 mg/kg) with Cat’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Testis 
Control 0.67 ±  0.02 
0.79 ± 
0.02 
6.01 ± 
0.09 
1.29 ± 
0.02 
0.54 ± 
0.02 
0.75 ± 
0.01 
Cat’s 
claw  
0.68 ± 
0.01 
0.81± 
0.04 
6.87 ± 
0.06* 
1.35 ± 
0.03 
0.56 ± 
0.03 
0.76 ± 
0.02 
*P< 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group. 
 
 
 
Table 1.14 Quantitative data on the average weight of selected organs of female mice 
(per 100 g body weight) after acute treatment (150 mg/kg) with Cat’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Ovaries 
Control 0.67 ±  0.02 
0.69 ± 
0.01 
5.90 ± 
0.02 
1.29 ± 
0.02 
0.55 ± 
0.08 
0.18 ± 
0.01 
Cat’s 
claw  
0.65 ± 
0.03 
0.68± 
0.03 
5.98 ± 
0.01 
1.34 ± 
0.04 
0.56 ± 
0.15 
0.19 ± 
0.02 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
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Table 1.15: Hematological studies on male mice after acute treatment (150 mg/kg) 
with Cat’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 6.12 ± 0.25 
7.40 ± 
0.11 
12.36 ± 
0.13 
438 ± 
21.30 
67.42 ± 
0.19 
38.58 ± 
0.09 
Cat’s 
claw  
4.94 ± 
0.21* 
7.32 ± 
0.10 
12.60 ± 
0.19 
496 ± 
24.50* 
69.19 ± 
0.22 
38.74 ± 
0.28 
*P < 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 1.16: Hematological studies on female mice after acute treatment (150 mg/kg) 
with Cat’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.94 ± 0.17 
7.28 ± 
0.15 
13.18 ± 
0.16 
464 ± 
27.30 
68.30 ± 
0.24 
38.42 ± 
0.29 
Cat’s 
claw  
5.30 ± 
0.19* 
7.32 ± 
0.19 
13.22 ± 
0.16 
485 ± 
30.61 
70.18 ± 
0.30 
39.26 ± 
0.17 
*P < 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 1.17: Biochemical studies on male mice after acute treatment (150 mg/kg) with 
Cat’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 17.6 ± 1.92 
11.08  ± 
1.29 
138.96 ± 
8.15 
127.56 ± 
3.12 
6.66 ± 
0.16 
5.64 ± 
0.12 
Cat’s 
claw  
31.2 ± 
3.45* 
18.58 ± 
2.36* 
135.17 ± 
7.38 
135.15 ± 
2.90 
8.30 ± 
0.44* 
5.89 ± 
0.08 
*P < 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 1.18: Biochemical studies on female mice after acute treatment with (150 
mg/kg) Cat’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 16.91 ± 1.50 
12.33  ± 
0.09 
130.91 ± 
7.90 
130.65 ± 
2.99 
6.66 ± 
0.16 
5.48 ± 
1.19 
Cat’s claw  20.40 ± 1.61* 
12.59 ± 
1.50* 
129.63 ± 
8.72 
132.39 ± 
4.61 
7.80 ± 
0.20* 
5.40 ± 
0.22 
*P < 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
Table 1.19: Clastogenic effects of Cat’s claw acute treatment (150 mg/kg) on the 
femoral cells in mice.  
Treatment 
Group 
Polychromatic 
Erythrocytes 
(PCE) 
Screened 
Micronucleated 
Polychromatic 
Erythrocytes(%)
Normochromatic 
Erythrocytes 
(NCE) Screened 
PCE / NCE 
Ratio 
Control 5137 0.30 ± 0.05 5000 1.03 ± 0.02 
Cat’s claw  5146 0.39 ± 0.09 5360 0.96 ± 0.03 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
  
         During sub-acute toxicity studies the body weight increase in the control male 
and female groups was significant (P<0.01). There was also a significant gain in the 
body weight (P<0.01) in the male treated group; however, the body weight changes in 
the female treatment group were non significant (Table 1.20).  
        There was no significant difference in the vital organ weights of animals in the 
treated groups as compared to the control except an increase (P< 0.05) in the weight 
of liver of male animals (Tables 1.21-1.22). Histopathological studies revealed normal 
heart, kidney, liver, lungs, testicles, pancreas, bone marrow, spleen, skeletal muscles 
and bone except mild congestion in liver and lungs. Hematological studies revealed 
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some decrease in WBC levels of Cat’s claw treated males and females as compared to 
the control, however, this decrease was statistically non-significant in female treated 
group (Tables 1.23-1.24). Biochemical studies showed a significant rise (P<0.01) in 
the levels of AST and ALT of Cat’s claw treated animals as compared to the control 
(Tables 1.25-1.26). Studies on the bone marrow revealed no clastogenic or cytotoxic 
effect in the treated groups as compared to the control (Table 1.27). 
 
Table 1.20: Quantitative data on body weight changes in mice after sub-acute 
treatment (50 mg/kg) with Cat’s claw. 
Male (g) Female (g) Treatment 
Group Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Control 24.48 ± 0.42 27.53 ± 0.89* 25.19 ± 0.25 27.00 ± 0.29** 
Cat’s claw  23.52 ± 0.39 27.23 ± 0.39** 24.83 ± 0.20 26.89 ± 0.19* 
*P < 0.05; ** P<0.01 (Student’s t-test). All results are expressed as: Average body 
weight ± S.E.  
Pre-treatment body weight was compared with post-treatment body weight.  
10 male and 10 female mice were used in each group. 
 
 
 Table 1.21 Quantitative data on the average weight of selected organs of male mice 
(per 100 g body weight) after sub-acute treatment (50 mg/kg) with Cat’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Testis 
Control 0.69 ±  0.01 
0.90 ± 
0.02 
6.76 ± 
0.21 
1.20 ± 
0.01 
0.54 ± 
0.01 
0.77 ± 
0.01 
Cat’s claw  0.70 ± 0.01 
0.90± 
0.02 
7.41 ± 
0.15* 
1.20 ± 
0.01 
0.52 ± 
0.02 
0.76 ± 
0.02 
*P < 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
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Table 1.22: Quantitative data on the average weight of selected organs of female 
mice (per 100 g body weight) after sub-acute treatment (50 mg/kg) with Cat’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Ovaries 
Control 0.69 ±  0.01 
0.90 ± 
0.02 
5.58 ± 
0.07 
1.20 ± 
0.01 
0.56 ± 
0.02 
0.10 ± 
0.01 
Cat’s claw  0.69 ± 0.01 
0.89± 
0.02 
5.56 ± 
0.05 
1.20 ± 
0.01 
0.55 ± 
0.01 
0.11 ± 
0.01 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
Table 1.23: Hematological studies on male mice after sub-acute treatment (50 mg/kg) 
with Cat’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 6.26 ± 0.20 
6.40 ± 
0.30 
11.02 ± 
0.19 
530 ± 
27.5 
65.30 ± 
0.66 
36.70 ± 
0.79 
Cat’s claw  5.50 ± 0.10* 
6.48 ± 
0.09 
11.94 ± 
0.25 
621 ± 
46.7* 
65.10 ± 
0.47 
37.10 ± 
0.55 
*P < 0.05, (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 1.24: Hematological studies on female mice after sub-acute treatment (50 
mg/kg) with Cat’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 6.32 ± 0.14 
6.66 ± 
0.28 
12.26 ± 
0.11 
500 ± 
36.21 
60.40 ± 
0.55 
32.40 ± 
0.45 
Cat’s claw  5.86 ± 0.18 
7.48 ± 
0.39 
12.80 ± 
0.18 
620 ± 
50.23* 
61.13 ± 
0.49 
33.16 ± 
0.59 
*P < 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 1.25: Biochemical studies on male mice after sub-acute treatment (50 mg/kg) 
with Cat’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 15.5 ± 0.93 
10.12  ± 
1.9 
165.60 ± 
15.55 
145.80 ± 
3.84 
5.70 ± 
0.42 
5.64 ± 
0.12 
Cat’s claw  23.8 ± 1.97** 
18.61 ± 
2.90* 
154.20 ± 
11.78 
142.70 ± 
4.23 
5.75 ± 
0.27 
5.78 ± 
0.09 
*P < 0.05, ** P < 0.01 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
Table 1.26: Biochemical studies on female mice after sub-acute treatment (50 mg/kg) 
with Cat’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 16.79 ± 0.92 
11.08  ± 
1.29 
138.86 ± 
7.91 
132.86 ± 
1.91 
5.53 ± 
0.53 
6.05 ± 
0.15 
Cat’s claw  23.8 ± 1.40** 
18.58 ± 
1.85** 
133.13 ± 
8.34 
130.06 ± 
1.80 
5.98 ± 
0.25 
6.06 ± 
0.18 
*P < 0.05, ** P < 0.01 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
Table 1.27: Clastogenic effects of Cat’s claw sub-acute treatment (50 mg/kg) on the 
femoral cells in mice.  
Treatment 
Group 
Polychromatic 
Erythrocytes 
(PCE) 
Screened 
Micronucleated 
Polychromatic 
Erythrocytes(%)
Normochromatic 
Erythrocytes 
(NCE) Screened 
PCE / NCE 
Ratio 
Control 5065 0.29 ± 0.03 4923 1.04 ± 0.06 
Cat’s claw  5156 0.29 ± 0.06  4796 0.99 ± 0.05 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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        During chronic toxicity studies there was a highly significant increase in the 
body weight of treated male and female animals (Table 1.28). This increase in the 
body weight was similar and comparable to the animals in the control groups.  
        The weight increase in liver and spleen of Cat’s claw treated male mice was 
significant (P<0.01) as compared to the control. There was reduction (P<0.05) in the 
weight of lungs in the treated male animals as compared to the control. In the treated 
female mice there was slight increase in weight of heart and liver (Tables 1.29-1.30).  
         Histopathological investigation of these organs, however, showed no significant 
changes and was found normal and comparable to the control (Microphotograph 1.1).           
Hematological studies on the chronically treated male and female mice revealed no 
appreciable differences as compared to the control, except mild increase in platelet 
count (Tables 1.31-1.32). Biochemical studies revealed a non-significant increase in 
AST and ALT in male treated group; however, this rise in the treated female group 
was statistically significant (Table 1.33-1.34). Chronic treatment with Cat’s claw 
induced no clastogenic or cytotoxic effect (Table 1.35).  
 
Table 1.28: Quantitative data on body weight changes in mice after chronic treatment 
(10 mg/kg/day) with Cat’s claw. 
Male (g) Female (g) Treatment 
Group Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Control 20.59 ± 0.32 36.60 ± 0.85* 21.78 ± 0.74 32.01 ± 0.30* 
Cat’s claw  20.86 ± 0.36 35.87 ± 0.49* 20.19 ± 0.37 31.42 ± 0.45* 
*P < 0.001 (Student’s t-test). All results are expressed as: Average body weight ± S.E.  
Pre-treatment body weight was compared with post-treatment body weight.  
10 male and 10 female mice were used in each group.  
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Table 1.29: Quantitative data on the average weight of selected organs of male mice 
(per 100 g body weight) after chronic treatment (10 mg/kg/day) with Cat’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Testis 
Control 0.73 ±  0.01 
1.50 ± 
0.05 
8.54 ± 
0.14 
2.40 ± 
0.10 
0.70 ± 
0.01 
1.32 ± 
0.05 
Cat’s claw  0.75 ± 0.01 
1.40± 
0.04* 
9.10 ± 
0.09* 
2.68 ± 
0.09 
0.77 ± 
0.02* 
1.42 ± 
0.07 
*P < 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
Table 1.30: Quantitative data on the average weight of selected organs of female 
mice (per 100 g body weight) after chronic treatment (10 mg/kg/day) with Cat’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Ovaries 
Control 0.73 ±  0.01 
1.34 ± 
0.05 
7.40 ± 
0.10 
2.12 ± 
0.07 
0.70 ± 
0.01 
0.12 ± 
0.01 
Cat’s claw  0.78 ± 0.03* 
1.28 ± 
0.06 
7.89 ± 
0.11* 
1.89 ± 
0.11 
0.70 ± 
0.01 
0.12 ± 
0.01 
*P < 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group. 
 
 
 
 
Table 1.31: Hematological studies on male mice after chronic treatment (10 
mg/kg/day) with Cat’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.86 ± 0.21 
6.74 ± 
0.24 
13.16 ± 
0.22 
522 ± 
15.1 
51.84 ± 
0.73 
38.48 ± 
0.46 
Cat’s claw  5.69 ± 0.23 
7.00 ± 
0.19 
13.66 ± 
0.26 
558± 
16.9* 
52.26 ± 
0.36 
39.60 ± 
0.32 
*P < 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 1.32: Hematological studies on female mice after chronic treatment (10 
mg/kg/day) with Cat’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 6.84 ± 0.22 
6.74 ± 
0.24 
12.78 ± 
0.18 
514 ± 
16.4 
51.92 ± 
0.43 
38.62 ± 
1.17 
Cat’s claw  5.69 ± 0.47 
6.92 ± 
0.22 
12.94 ± 
0.33 
555 ± 
28.9 
52.12 ± 
0.35 
39.40 ± 
0.33 
P > 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 1.33: Biochemical studies on male mice after chronic treatment (10 mg/kg/day) 
with Cat’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 15.5 ± 0.54 
10.34  ± 
1.45 
144.70 ± 
15.91 
149.11 ± 
1.53 
5.85 ± 
0.37 
5.64 ± 
0.09 
Cat’s claw  21.0 ± 3.70 
12.98 ± 
0.64* 
154.68 ± 
20.41 
153.61 ± 
2.29 
6.30 ± 
0.87 
5.57 ± 
0.016 
*P < 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 1.34: Biochemical studies on female mice after chronic treatment (10 
mg/kg/day) with Cat’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 16.61 ± 0.97 
11.18  ± 
1.30 
138.85 ± 
8.32 
145.39 ± 
3.18 
5.77 ± 
0.50 
5.89 ± 
0.09 
Cat’s claw  17.19 ± 0.56* 
18.98 ± 
1.26* 
137.31 ± 
9.18 
141.30 ± 
4.26 
5.04 ± 
0.25 
5.93 ± 
0.12 
*P < 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 1.35: Effects of chronic treatment (10 mg/kg/day) with Cat’s claw on the 
femoral cells in mice.  
Treatment 
Group 
Polychromatic 
Erythrocytes 
(PCE) 
Screened 
Micronucleated 
Polychromatic 
Erythrocytes(%)
Normochromatic 
Erythrocytes 
(NCE) Screened 
PCE / NCE 
Ratio 
Control 5200 0.23 ± 0.04 5060 1.04 ± 0.07 
Adriamycin 5000 5.32 ± 0.33** 7596 0.67 ± 0.04* 
Cat’s claw  4993 0.27 ± 0.03 5360 0.83 ± 0.09 
*P < 0.05, ** P < 0.01 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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                          Heart                              Kidney 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                           Liver       Lung                           
                                                  
Microphotograph 1.1: A section through the Heart, Kidney, Liver and Lung of mice 
after chronic treatment with Cat's claw capsules showing normal appearance 
(Hematoxyline and eosin X 400). 
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Microphotograph 1.2: A section through the Heart, Kidney, Liver and Lung of mice 
from the control group after chronic treatment showing normal appearance.                                      
Hematoxyline and eosin X 400).       
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    3.1.7  Discussion      
          The significant rise observed in the liver enzymes caused by Cat’s claw 
treatment during current acute and sub-acute toxicity studies might be attributed to the 
constituents of Cat’s claw inducing hepatic cellular action. Oleanolic acid, 
(−)-epicatechin and (+)-catechin (cianidol) are known to possess anti-inflammatory 
and anticancer effect (Kapil and Sharma 1995; Otsuka et al., 1982, Keeling et al., 
1986, Azuine and Bhide 1994, Noreen et al., 1998) while sterols such as β-sitosterol 
and stigmasterol and triterpenoids possess antihypercholesterolemic and anti-
inflammatory properties (Gupta et al., 1980, Chandler et al., 1979, Recio 1995). On 
the other hand, quinovic acid glycoside showed anti-inflammatory and antiviral 
activity (Ahmad et al., 1990; Aquino et al., 1991, Cerri et al., 1988) while ajmalicine 
derivatives are known for their inhibitory action on platelet aggregation (Chan-Xun 
1992, Jin et al, 1991, Neumann et al., 1986). Pentacyclic oxindole alkaloids of Cat’s 
claw were reported to induce human endothelial cells to release a lymphocyte-
proliferation-regulating factor (Wurm et al., 1998). Earlier cianidol and catechin 
treatment in rats was found to induce no changes in bilirubin transport capacity (Ricci 
et al., 1986). Lupeol and ellagic acid are known antioxidants and tumor inhibitors 
(Miles and Kokpol, 1976, Murakami and Yam Fuji, 1969, Ruffauf et al., 1978, Daniel 
et al.,, 1991, Trumbull et al., 1976). The antitumor activity of Cat’s claw was 
confirmed by Sheng et al. (1993). Canovic acid, gallic acid and pyrogallol are known 
for their antitumor potential (Raffauf et al., 1978, Aquino et al., 1989, Heur et al., 
1992, Murakami and Yam Fuji, 1969, Saeed and Hamdy, 1996). Cat’s claw was also 
found to show antimutagenic properties (Rizzi 1990, 1993). The increase observed in 
urea, AST and ALT levels of animals in the treatment groups during the current acute 
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and sub-acute toxicity studies in the given dose of Cat’s claw may be attributed to 
some of these active compounds of Cat’s claw.  
        The chemical constituents of Cat’s claw possessing significant antitumor activity 
may also be held responsible for the reduced levels of WBC in some animals 
observed during the current experiments. However, Histopathological studies on 
different organs of Cat’s claw treatment groups (acute and sub-acute treatment 
groups) showed normal appearance of all vital organs, except mild congestion with 
microscopic foci of inflammatory changes seen in liver. These results are in 
agreement with the observed rise in liver enzymes of the treated animals. Cat’s claw 
alkaloids Rhynchophylline, Hirsutine, and Mitraphylline have been reported to 
possess vasodilating properties (Yano, 1991), which may explain the mild congestion, 
observed in liver. It is worth mentioning that there were no necrotic changes in the 
liver of treated animals. Our histopathology results are in agreement with earlier 
finding where Cat’s claw alkaloids were found not to cause hepatic damage (Toure et 
al. 1996).  
         Speciophylline, a biologically active alkaloid present in Cat’s claw showed 
obvious hepatic cellular activity with no hepatotoxic effect. Speciophylline was found 
superior to sodium dehydrocholate in increasing biliary flow (Toure et al., 1996). 
Furthermore, the triterpenes such as ursolic acid and sterols present in Cat’s claw are 
known to possess significant hypolipidemic, antiulcer and diuretic activities. 
However, ursolic acid was reported not to alter cholesterol and beta-lipoprotein levels 
in the liver of treated animals (Vasilenko et al., 1982, Parfent-eva, 1980, Farina et al., 
1998). Keeping in view the toxicity results of Cat’s claw acute and sub-acute 
treatment, the chronic toxicity experiment is considered essential to evaluate the 
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toxicity of Cat’s claw. During acute and sub acute treatment Cat's claw failed to elicit 
any clastogenic effect. 
         During chronic toxicity studies there was a highly significant increase in the 
body weight of treated male and female animals (Table 1.28). This increase in the 
body weight was similar and comparable to the animals in the control groups.  
        The weight increase in liver and spleen of Cat’s claw treated male mice was 
significant (P<0.01) as compared to the control. There was reduction (P<0.05) in the 
weight of lungs in the treated male animals as compared to the control. In the treated 
female mice there was slight increase in weight of heart and liver (Tables 1.29-11.30).  
         Histopathological investigation of these organs, however, showed no significant 
changes and was found normal and comparable to the control (Microphtograph 1.1).  
Hematological studies on the chronically treated male and female mice revealed no 
appreciable differences as compared to the control, except mild increase in platelet 
count (Tables 1.31-1.32). Biochemical studies revealed a non-significant increase in 
AST and ALT in male treated group; however, this rise in the treated female group 
was statistically significant (Table 1.33-1.34).  Chronic treatment with Cat’s claw 
induced no clastogenic or cytotoxic effect (Table 1.35).  
         Five of the oxindole alkaloids of Cat’s claw have been clinically documented 
with antileukemic, antitumor and antimutagenic properties. The bark and roots of 
Cat’s claw possesses significant immunostimulating actions due to the presence of 
oxindole alkaloids (Kiplinger 1989, 1992, 1994). Oxindole alkaloids were 
demonstrated to increase immune function by up to 50% in relatively small amounts 
(Sheng et al., 1998; WHO. 1994). 
        Contrary to our results of acute and sub-acute toxicity studies the WBC counts 
during chronic toxicity studies were found in the normal range and comparable to the 
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control. This shift may be attributed to the appropriate dose used during chronic 
toxicity experiment. Furthermore, the pentacyclic oxindole alkaloids of Cat’s claw are 
known to produce a lymphocyte-proliferation-regulating factor, which normalizes the 
lymphocyte count without altering the total leukocyte numbers (Kiplinger et al., 
1999). In addition to normalizing the lymphocyte count, the total oxindole contents of 
Cat’s claw were found to stimulate IL-1 and IL-6 production by rat macrophages 
proving strong immuno-stimulant action of this plant (Lemaire et al., 1999). The 
increase in platelet count observed in the present study may be attributed to the 
chemical constituents of Cat’s claw, which stimulate interleukins. No clastogenic or 
cytotoxic effects were observed during the current study in the animals.  
          The results of our current study add support to the earlier reports indicating 
pharmacological properties of Cat’s claw with relatively low toxicity (Jones 1995, 
Santa Maria et al., 1997). However, due to its pharmacological activities, Cat’s claw 
was earlier suggested to be used with caution while using drugs such as: lovastatin 
(Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), 
and triazolam (Halicion) (Steinberg, 1994, Krallendorn, 1995, Steinberg, 1995). 
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3.2  Results for Devil's claw 
 
  
 
 
 
 
 
 
 
 
 
 
                    Figure 2.1:  A typical HPLC chromatogram of Harpagoside 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2:  A typical HPLC chromatogram of the contents of Devil's claw capsules. 
 
 
 
 
 
 73
3.2.1.  Method validation:  
         Method validation establishes that the method performance characteristics are 
suitable for the intended use. Validation initials evaluation of various parameters of 
the method such as selectivity, accuracy, precision, linearity (concentration-detector 
response relationship) sensitivity, detection and quantitation limits and recovery 
percentage.   
3.2.1.1  System suitability:  
        The reported method was adopted to follow harpagoside standard and good 
separation for active ingredients in Devil's claw capsules and other compounds 
(Figure 2.1-2.2). This method can thus be considered a stability indicating one. 
Number of theoretical plates, capacity factor, resolution, and asymmetry, width at 5% 
height and United States Pharmacopoeia (USP) width are collected in Table 2.2.  
 
Table 2.2:  System suitability parameters.  
RT Theoretical plates 
Capacity 
factor K Resolution Asymmetry
USP 
width 
Width at 
5% height 
7.7 6190 2.47 2.08 0.95 0.39 0.23 
 
3.2.1.2.  Selectivity:  
 For chromatographic methods specificity is the ability of a method to 
accurately measure the analyte response in presence of all potential sample 
components; the selectivity criterion for an assay method is that analyte peaks with 
suitable resolution from all other sample components (see Figures 2.1-2.2).  
 
3.2.1.3. Linearity:  
        The calibration graph was prepared by plotting the peak area of standard 
harpagoside (Figure 2.3) alternatively the following regression equation was derived.  
 74
Y = 0.0477x - 0.0089
R2 = 0.9998
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Where Y = Peak area and x = Concentration in µg/ml.  
For testing the linearity the following solutions were prepared (Table 2.2). 
  
Table 2.3: Standard solutions for testing linearity.  
S. No. Con in µg/ml. Peak area of harpagoside standard. 
1. 10 0.47*106 
2. 20 0.95*106 
3. 30 1.42*106 
4. 40 1.86*106 
5. 50 2.37*106 
6. 60 2.85*106 
7. 70 3.34*106 
8. 80 3.82*106 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3:  The Calibration curve for harpagoside using HPLC method. 
 
 
3.2.1.4.  Precision:  
        The validity of the method was proved by analyzing six injections of harpagoside 
with concentration of 50µg/ml. The percentage recovery was found to be 100.22± 
0.56% (Table 2.4).  
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Table 2.4: Results of the six injections from the standard of harpagoside (50µg/ml). 
S. No. Calculated concentration (µg/ml) Recovery % 
1. 50.40 100.79 
2. 50.50 100.99 
3. 49.78 99.57 
4. 50.07 100.14 
5. 49.92 99.84 
6. 49.98 99.97 
Average 50.11 100.22 
RSD %  0.556 
 
 
3.2.1.5. Accuracy and Recovery:  
        The accuracy of the method was proved by analyzing six replicates with different 
concentrations of harpagoside (over the lower concentration 10.4 µg/ml and higher 
concentration 104 µg/ml). Each injection was repeated of three and the percentage 
recovery was calculated according to Cuadros et al. (1995). The recovery was found 
to be 100.48±0.14% for lower concentration and 99.18±0.40% for higher 
concentration (Table 2.5).  
Table 2.5: Showing six injections from each concentration for the accuracy 
determination.  
S. No. Concentration 10.4 µg/ml 
Recovery 
% S. No. 
Concentration 
104 µg/ml 
Recovery 
% 
1. 10.44 100.37 1 103.22 99.25 
2. 10.45 100.51 2. 102.78 98.83 
3. 10.46 100.53 3. 102.84 98.88 
4. 10.45 100.49 4. 103.92 99.92 
5. 10.47 100.67 5. 103.12 99.15 
6. 10.43 100.25 6. 102.98 99.02 
Average 10.45 100.48 Average 103.14 99.18 
RSD %  0.136 
 
RSD %  0.399 
 
3.2.1.6.  Limit of detection and quantitation:  
        The detection limit (LOD) of a method is the lowest analyte concentration that 
produces response detection above the noise level of system, typically takes as three 
times the noise level. The quantitation limit (LOQ) is the lower level of analyte that 
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can be accurately measured, and it is often evaluated as ten times the noise level. Both 
detection and quantitation limits need to be determined only for impurity methods. In 
our case, the proposed method is for assay of harpagoside in Devil's claw capsules, 
we have evaluated both quantities according to the procedure of Miller and Miller 
(1988) calculated as three and ten times, respectively.  
        The minimum concentration of which harpagoside could reliably be detected or 
quantified were established by comparing the measured signals from samples with 
those of blank (Methanol). According to the described condition the sensitivity results 
were:  
Limit of detection (LOD) = 0.05 µg/ml; Limit of quantification (LOQ) = 0.1 µg/ml  
3.2.2.  Effect of Temperature: 
        The effect of rise of temperature on the rate of reaction is given by Arrhenius 
Law which shows an exponential relation between the rate constant (K) and 
temperature (Keaneth, et al. 1984; Martin 1993).  
 K = Ae− Ea/RT 
Where K stands for the rate constant, Ea is the activation energy, R is the universal 
gas constant (1.98 Cal/mol-degree), Ae is the exponential and T is the absolute 
temperature.  
        All kinetic experiments were performed at controlled temperature at t ±1oc where 
t=25, 30, 35 oc with 75% humidity. All reactions were run under first order conditions. 
The apparent rate constants were obtained from the slopes of semi logarithmic linear 
plots using the lest squares method.  
        Devil's claw capsules and harpagoside standard were stored under different 
simulated climatic conditions:  
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4. Climatic chamber CH1 (25ºC ± 1ºC; RH = 75%) 
5. Climatic chamber CH2 (30ºC ± 1ºC; RH = 75%) 
6. Climatic chamber CH3 (35ºC ± 1ºC; RH = 75%) 
  The samples were studied for 24 months. The samples from different conditions 
were drawn every six months and subjected to different analysis.  
        Assay of harpagoside and Devil's claw capsules was made at different time 
intervals and conditions according to the developed and validated HPLC method. The 
concentration of harpagoside was followed by injecting 20 µl. The concentration of 
intact harpagoside was calculated from the standard curve plotted as peak area of 
standard harpagoside versus the concentration (Figure 2.3) . 
Table 2.6: %w/v of harpagoside in Devil's claw capsules  at different time intervals 
and temperature.  
Time /month CH 1 % CH 2 % CH 3 % 
0 100 100 100 
 6 99.79 99.5 98.92 
12 98.91 98.69 97.72 
18 98.14 97.75 96.81 
24 96.95 96.91 95.61 
 
Table 2.7: %w/v of harpagoside reference material at different time intervals and 
temperatures.  
Time /month CH 1 % CH 2 % CH 3 % 
0 100 100 100 
6 98.52 98.04 96.81 
12 94.20 94.10 93.10 
18 93.50 88.00 83.10 
24 88.09 81.07 69.38 
 
Table (2.6) clearly shows that harpagoside in Devil's claw capsules is stable over the 
range of 25ºC, 30ºC and 35ºC with humidity 75%. Harpagoside in Devil's Claw 
capsules undergoes slight decomposition and it loses about 0.21%, 0.5% and 1.08% 
for six months at CH1, CH2 and CH3 conditions, respectively. The rate of 
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decomposition increases and it loses around 3.05%,3.09 % and 4.39% after 24 months 
at CH1, CH2 and CH3 respectively.   
The results of table (2.7) clearly shows that the harpagoside standard is unstable over 
the range of 25ºC, 30ºC and 35ºC with humidity 75%. Harpagoside however 
undergoes slight decomposition and it loses about 1.48%, 1.96% and 3.19% for six 
months at CH1, CH2 and CH3 respectively. The rate of decomposition increases and 
it loses around 11%, 18% and 29% after 24 months at CH1, CH2, and CH3, 
respectively. The kinetic parameters for the degradation of harpagoside under 
different temperature 25ºC, 30ºC and 35ºC with humidity 75% were found to be first-
order condition. The semi-logarithmic plots of  log (a/a-x) against time (t) were found 
to be straight line with a slope of 0.0023, 0.0038 and 0.0066 CH1, CH2 and CH3 
respectively as shown in Figure 2.4 using the formula for the first-order reaction 
kinetics. 
xa
a
−= log2.303
kt
 
        The reaction rate constant (K) was found to be 0.00529, 0.00875 and 0.0152 
month-1 to CH1, CH2 and CH3, respectively. The half life time t1/2 was obtained from 
the following formula: 
k
693.0t1/2 =  and was found to be 131, 79.2 and 45.6 months 
for CH1, CH2 and CH3, respectively.  
         The activation energy (Ea) was obtained from the following formula: 
2 1TT R303.2
)12( 
k1
k2 log TTEa −= . 
 The average of activation energy was also calculated and was found to be 18.97 
kcal/mole. This value lies within typical range of 10-30 Kcal/mole estimated for 
hydrolysis reactions (Fung L.H et al 1990). Harpagoside contain ester functional 
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groups. Its degradation may involve this group. All these results are collected in Table 
2.8.  
         Systemic studies were carried out at several degrees, in the range 25, 30 and 
35°C with 75 % humidity (Figure 2.4) and show the effect of temperature on the 
degradation of harpagoside over the range 25, 30 and 35°C with 75 % humidity. The 
rate constant at each temperature was determined from a suitable plot, and Log K was 
plotted against the reciprocal of temperature (1/T). From the slope of such plots, the 
activation energy was calculated as shown in (Figure 2.5). The magnitude of the 
activation energy measures the energy barrier separating reactants from products. The 
smaller the value of the activation energy, the easier is the crossing of the energy 
barrier, and hence the occurrence of the reaction is more likely. The reaction rate 
constant was calculated at each temperature and the activation energy was calculated 
from the following relation:  
21
12
1
2
303.2
)(
TRT
TTE
K
KLog a −=  
Where K2 and K1 are the rate constants at T2 and T1, respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Stability studies on Harpagoside exposed to different simulated climatic 
conditions. 
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Figure 2.5: Arrhenius plot for harpagoside standard at different temperatures. 
 
 
Table 2.8: Effect of temperature on the kinetic parameters of harpagoside (2.5 
µg/ml). 
Temp °C Slope K(month) Log K t ½(month) Ea(K. cal. 
Mole) 
CH1 0.0023 0.00529 −2.28 131 
CH2 0.0038 0.00875 −2.05 79.2 
CH3 0.0066 0.0152 −1.81 45.6 
  
  
 
 Average activation energy        18.97 
 
 
 
 
 
 
 
 
 
 
 
 
 
17.5 
20.5 
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3.2.3.  Elemental Analysis:  
         Devil's claw was found to contain magnesium, calcium and sodium in relatively 
large amount. The amount of potassium was also high. No other element especially 
heavy metals were found (Table 2.9).  
Table 2.9:  Elemental analysis results of Devil's claw.  
 Element Results (µg/g) Element Results (µg/g)
Sodium 3308 Potassium 11272 
Calcium 2837 Magnesium 4083 
Iron NF Copper NF 
Chromium NF Manganese NF 
Lead NF Mercury NF 
Cadmium NF Arsenic NF 
NF = Not found.  
 
3.2.4.   Physical examination:  
        The Devil's claw powder and shell were examined over the period of 24 months. 
The powder retained its beige color and no distinctive odor was noticed except after 
24 months in CH2 and CH3 condition they became dark brown color. Similarly, the 
capsule shell remained transparent and colorless over the same period except after 24 
months in CH2 and CH3 where it attained the shape of a cylindrical lump with dark 
brown color.  
3.2.5.  Microbiological studies:  
        The drug samples were tested using standard protocol for the total viable count 
for bacteria, fungi, Escherichia coli, Staphylococcus Aureus, Pseudomonas 
aeruginosa and salmonella. The results are presented in the following (Table 2.10). 
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Table 2.10 Microbiological counting on Devil's claw capsules stored at different 
climatic chambers. 
‘Microbial counts − Devil's  claw capsules’ (Storage Location) 
CH 1 CH 2 CH 3 Duration (Month) 
B F B F B F 
Zero time <10 <10 <10 <10 <10 <10 
0+6 <10 <10 <10 <10 <10 <10 
0+12 <10 <10 <10 <10 <10 <10 
0+18 <10 <10 <10 <10 <10 <10 
0+24 <10 <10 <10 <10 <10 <10 
CH1: Climatic Chamber No. 1 (25°C±1°C-humidity 75%). 
CH2: Climatic Chamber No. 2 (30°C ± 1°C-humidity 75%). 
CH3: Climatic Chamber No. 3 (35°C ± 1°C-humidity 75%). 
B: Total viable count of aerobic bacteria in colony forming unit/gm. 
F: Total viable count of fungi in colony forming unit/gm. 
 
        The results of the microbiological studies revealed no significant changes in total 
viable aerobic count of bacteria and fungi. As shown in Table 2.10 the total count of 
viable aerobic bacteria and fungi was less than 10 cfu, regardless of storage 
conditions. These results clearly demonstrate the microbiological stability of Devil's 
claw capsules. The results also indicate that the primary pathogens Escherichia coli, 
Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella were not present in 
all the tested samples of Devil's claw capsules.  
 
3.2.6. Toxicity Studies:  
         During acute toxicity studies on Devil’s claw (Harpagophytum procumbent) 
observations were made at 5, 15, 30 minutes and 4 hours after single acute dose 
treatment followed by observations for any toxicity signs and symptoms once daily 
for 7 days. Devil’s claw treated animals exhibited no alarming signs of toxicity and 
none of the animals died during the observation period. The body weight changes in 
both the male and female treated groups were found comparable to the changes 
observed in the respective control groups (Table 2.11). At the end of the treatment the 
weight of the vital organs and condition of the viscera were normal and comparable to 
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the control (Tables 2.12-2.13). The results of histopathological studies also revealed 
all organs to be normal and comparable to the control. The results of the 
hematological studies revealed no significant differences between the treated groups 
and the control groups (Tables 2.14-2.15). All biochemical parameters remained 
normal and comparable to the control (Tables 2.16-2.17). Devil’s claw acute 
treatment showed no cytotoxic or clastogenic effect in the femoral cells of mice 
(Table 2.18). All these results clearly indicate that Devil’s claw acute treatment is 
devoid of any toxicity. However sub-acute and chronic toxicity experiments were 
considered essential to evaluate any toxic signs in treated animals.  
 
 
 
Table 2.11: Quantitative data on body weight changes in mice after acute treatment 
(81 mg/kg) with Devil’s claw. 
Male (g) Female (g) Treatment 
Group Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Control 20.30 ± 1.2 22.40 ± 1.25* 21.20 ± 1.0 22.60 ± 1.1* 
Devil’s claw 20.50 ± 1.3 22.80 ± 1.00* 20.82 ± 1.3 22.70 ± 1.4* 
*P < 0.05 (Student’s t-test). All results are expressed as: Average body weight ± S.E.  
Pre-treatment body weight was compared with post-treatment body weight.  
10 male and 10 female mice were used in each group.  
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Table 2.12: Quantitative data on the average weight of selected organs of male mice 
(per 100 g body weight) after acute treatment (81 mg/kg) with Devil’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Testis 
Control 0.67 ±  0.03 
0.78 ± 
0.01 
5.90 ± 
0.12 
1.20 ± 
0.02 
0.55 ± 
0.01 
0.72 ± 
0.01 
Devil’s 
claw 
0.66 ± 
0.02 
0.77± 
0.02 
5.94 ± 
0.13 
1.21 ± 
0.07 
0.55 ± 
0.01 
0.72 ± 
0.01 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
Table 2.13: Quantitative data on the average weight of selected organs of female 
mice (per 100 g body weight) after acute treatment (81 mg/kg) with Devil’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Ovaries 
Control 0.65 ±  0.01 
0.76 ± 
0.01 
5.90 ± 
0.12 
1.22 ± 
0.02 
0.55 ± 
0.01 
0.10 ± 
0.01 
Devil’s 
claw 
0.65 ± 
0.01 
0.78± 
0.04 
5.94 ± 
0.14 
1.30 ± 
0.12 
0.55 ± 
0.01 
0.11 ± 
0.01 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
 
Table 2.14: Hematological studies on male mice after acute treatment (81 mg/kg) 
with Devil’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.71 ± 0.50 
6.10 ± 
0.60 
12.9 ± 
0.35 
484 ± 
28.0 
51.5 ± 
0.9 
38.7 ± 
0.80 
Devil’s 
claw 
5.90 ± 
0.36 
6.12 ± 
0.20 
12.9 ± 
0.13 
491 ± 
23.0 
51.8 ± 
2.0 
38.4 ± 
0.63 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 2.15: Hematological studies on female mice after acute treatment (81 mg/kg) 
with Devil’s claw  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.14 ± 0.40 
6.21 ± 
0.63 
12.5 ± 
0.32 
464 ± 
20.0 
51.06 ± 
0.45 
38.4 ± 
0.63 
Devil’s 
claw 
5.30 ± 
0.31 
6.02 ± 
0.44 
12.8 ± 
0.50 
483 ± 
18.0 
51.84 ± 
2.34 
38.3 ± 
0.77 
P > 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
 
Table 2.16: Biochemical studies on male mice after acute treatment (81 mg/kg) with 
Devil’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 16.0 ± 0.58 
11.15  ± 
1.50 
145.8 ± 
15.61 
132.86 ± 
2.21 
5.84 ± 
0.35 
5.42 ± 
0.09 
Devil’s 
claw 
17.9 ± 
0.63 
12.09 ± 
1.16 
144.3 ± 
12.91 
134.01 ± 
3.69 
5.82 ± 
0.37 
5.09 ± 
0.06 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
 
Table 2.17: Biochemical studies on female mice after acute treatment (81 mg/kg) 
with Devil’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 15.31 ± 0.52 
11.12  ± 
0.70 
140.5 ± 
14.60 
99.57 ± 
3.61 
5.53 ± 
0.29 
5.45 ± 
1.02 
Devil’s 
claw 
16.38 ± 
0.70 
13.61 ± 
1.55 
145.7 ± 
14.91 
96.39 ± 
4.92 
4.78 ± 
0.31 
5.44 ± 
1.51 
P > 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 2.18: Clastogenic effects of Devil’s claw acute treatment (81 mg/kg) on the 
femoral cells in mice.  
Treatment 
Group 
Polychromatic 
Erythrocytes 
(PCE) 
Screened 
Micronucleated 
Polychromatic 
Erythrocytes(%)
Normochromatic 
Erythrocytes 
(NCE) Screened 
PCE / NCE 
Ratio 
Control 5253 0.30 ± 0.05 5231 1.01 ± 0.02 
Devil’s claw 5400 0.29 ± 0.06 6264 0.86 ± 0.10 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
         During sub-acute toxicity studies, the post-treatment body weight increase in 
Devil’s claw treated male and female groups was statistically significant (P < 0.05) as 
compared to the pre-treatment body weights of the animals and these changes were 
comparable to the respective control groups (Table 2.19). At the end of the treatment 
the average weight of the vital organs and condition of the viscera were normal and 
comparable to the control (Tables 2.20-2.21). Histopathological investigations 
confirmed heart, lungs, liver, kidneys, spleen, ovaries and testicles of all the treated 
animals in different groups to be normal and comparable to the control. The results of 
the hematological studies revealed no significant differences between the treatment 
groups and control groups (Tables 2.22-2.23).  Biochemical studies revealed that AST 
levels in the female treated group were elevated (P < 0.05) as compared to the control.  
However, there was no significant effect on ALT levels of the female treated group 
(Tables 2.24-2.25). Studies on the femoral cells revealed no significant effect as 
compared to the control indicating Devil’s claw to be devoid of clastogenic and 
mitodepressant activities in the given dose (Table 2.26).  
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Table 2.19: Quantitative data on body weight changes in mice after sub-acute 
treatment (27 mg/kg) with Devil’s claw. 
Male (g) Female (g) Treatment 
Group Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Control 21.8 ± 0.42 23.53 ± 0.58* 22.3 ± 0.55 24.8 ± 0.49* 
Devil’s claw 20.1 ± 0.90 24.81 ± 0.70** 20.5 ± 0.60 23.6 ± 0.70* 
*P<0.05, ** P <0.01 (Student’s t-test).  
All results are expressed as: Average body weight ± S.E.  
Pre-treatment body weight was compared with post-treatment body weight.  
10 male and 10 female mice were used in each group. 
 
 
 
Table 2.20: Quantitative data on the average weight of selected organs of male mice 
(per 100g body weight) after sub-acute treatment (27 mg/kg) with Devil’s claw.  
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
Table 2.21: Quantitative data on the average weight of selected organs of female 
mice (per 100 gm body weight) after sub-acute treatment (27 mg/kg) with Devil’s 
claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Ovaries  
Control 0.52 ±  0.03 
0.87 ± 
0.04 
6.85 ± 
0.24 
1.55 ± 
0.07 
0.74 ± 
0.05 
0.10 ± 
0.04 
Devil’s 
claw 
0.56 ± 
0.04 
0.89± 
0.05 
6.89 ± 
0.20 
1.53 ± 
0.06 
0.81 ± 
0.06 
0.10 ± 
0.02 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
Mean organ weight per 100g body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Testis 
Control 0.57 ±  0.02 
0.86 ± 
0.06 
6.62 ± 
0.38 
1.47 ± 
0.04 
0.63 ± 
0.08 
0.72 ± 
0.05 
Devil’s 
claw 
0.56 ± 
0.02 
0.89± 
0.11 
6.69 ± 
0.62 
1.46 ± 
0.04 
0.65 ± 
0.07 
0.75 ± 
0.10 
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Table 2.22: Hematological studies on male mice after sub-acute treatment (27 mg/kg) 
with Devil’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.90 ± 0.75 
6.15 ± 
0.38 
13.2 ± 
0.30 
495 ± 
17.0 
52.3 ± 
0.40 
39.10 ± 
0.50 
Devil’s 
claw 
6.12 ± 
0.63 
5.60 ± 
0.30 
13.0 ± 
0.68 
502 ± 
32.0 
53.0 ± 
3.5 
39.00 ± 
0.70 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 2.23: Hematological studies on female mice after sub-acute treatment (27 
mg/kg) with Devil’s claw.  
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 6.30 ± 1.06 
5.08 ± 
0.22 
10.62 ± 
0.79 
533 ± 
79.0 
51.80 ± 
0.90 
27.80 ± 
2.90 
Devil’s 
claw 
5.98 ± 
0.98 
5.13 ± 
0.20 
11.22 ± 
0.914 
495 ± 
65.0 
51.00 ± 
1.90 
27.50 ± 
2.39 
P > 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
Table 2.24: Biochemical studies on male mice after sub-acute treatment (27 mg/kg) 
with Devil’s claw.  
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 15.0 ± 0.54 
10.34  ± 
1.44 
146.70 ± 
15.96 
151.11 ± 
2.53 
5.85 ± 
0.38 
5.64 ± 
0.07 
Devil’s 
claw 
15.85 ± 
0.73 
12.79 ± 
2.88 
140.63 ± 
14.52 
157.67 ± 
4.13 
5.95 ± 
0.34 
5.61 ± 
0.19 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 2.25: Biochemical studies on female mice after sub-acute treatment (27 mg/kg) 
with Devil’s claw. 
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 16.61 ± 0.92 
11.90  ± 
1.30 
138.96 ± 
8.15 
145.80 ± 
3.84 
7.30 ± 
0.50 
6.10 ± 
0.75 
Devil’s 
claw 
21.0 ± 
2.74* 
14.80 ± 
3.91 
111.30 ± 
9.64 
141.13 ± 
2.98 
6.92 ± 
0.40 
5.49 ± 
0.46 
*P < 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
Table 2.26: Clastogenic effects of Devil’s claw sub-acute treatment (27 mg/kg) on 
the femoral cells in mice.  
Treatment 
Group 
Polychromatic 
Erythrocytes 
(PCE) 
Screened 
Micronucleated 
Polychromatic 
Erythrocytes(%)
Normochromatic 
Erythrocytes 
(NCE) Screened 
PCE / NCE 
Ratio 
Control 5519 0.29 ± 0.03 5000 1.10 ± 0.03 
Devil’s claw 5112 0.35 ± 0.04 6016 0.88 ± 0.07 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
        During chronic toxicity studies, no toxic symptoms were noticed in the treated 
groups over the period of three months. The increase in water in-take during the 
period of chronic toxicity studies was comparable to the water consumption in the 
control groups. All animals in the control and treatment groups were found healthy 
and active. There was a significant and similar weight gain in all the animals of the 
control and treated groups Table (2.27) At the end of the treatment the visceral 
conditions of all animals in the treated groups were normal and comparable to the 
control (Tables 2.28-2.29). It is worth mentioning that during histopathological 
studies (Microphotograph 2.1) all the vital organs of the treated groups were found to 
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be normal and comparable to the control. There was statistically non-significant effect 
on the bone marrow cells of treated group as compared to the control.  
        The results of the hematological studies revealed no significant differences 
between the treated groups and control groups (Tables 2.30-231). All biochemical 
parameters remained normal and comparable to the control (Tables 2.32-233).  
        Adriamycin treatment, however, caused significant (P < 0.01) increase in 
micronucleated polychromatic erythrocytes and reduction in PCE/NCE ratio 
confirming its known clastogenic and cytotoxic potential (Table 2.34). 
 
Table 2.27: Quantitative data on body weight changes in mice after chronic treatment 
(5.4 mg/kg) with Devil’s claw. 
Male (g) Female (g) Treatment 
Group Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Control 20.4 ± 1.30 34.7 ± 2.60* 21.5 ± 1.00 32.01 ± 0.70* 
Devil’s claw  22.3 ± 2.17 34.9 ± 3.10* 22.1 ± 2.63 31.8 ± 0.58* 
*P < 0.001 (Student’s t-test). All results are expressed as: Average body weight ± S.E.  
Pre-treatment body weight was compared with post-treatment body weight.  
10 male and 10 female mice were used in each group.  
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Table 7.28: Quantitative data on the average weight of selected organs of male mice 
(per 100 gm body weight) after chronic treatment (5.4 mg/kg) with Devil’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Testis 
Control 0.64 ±  0.03 
0.77 ± 
0.04 
6.75 ± 
0.20 
1.67 ± 
0.06 
0.62 ± 
0.05 
0.70 ± 
0.02 
Devil’s 
claw 
0.68 ± 
0.56 
0.79 ± 
0.06 
7.01 ± 
0.40 
1.69 ± 
0.07 
0.68 ± 
0.07 
0.72 ± 
0.02 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
Table 2.29: Quantitative data on the average weight of selected organs of female 
mice (per 100 gm body weight) after chronic treatment (5.4 mg/kg) with Devil’s claw. 
Mean organ weight per 100 gm body weight ± S. E. Treatment 
Group Heart Lungs Liver Kidney Spleen Ovaries  
Control 0.62 ±  0.02 
0.77 ± 
0.04 
6.75 ± 
0.20 
1.67 ± 
0.06 
0.62 ± 
0.05 
0.12 ± 
0.01 
Devil’s 
claw 
0.67 ± 
0.17 
0.79 ± 
0.05 
6.88 ± 
0.25 
1.73 ± 
0.06 
0.65 ± 
0.10 
0.12 ± 
0.01 
P > 0.05 (Student’s t-test). 
The treatment group was compared with the control group.  
Five randomly selected animals were used in each group.  
 
 
 
Table 2.30: Hematological studies on male mice after chronic treatment (5.4 mg/kg) 
with Devil’s claw. 
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g /dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.70 ± 0.45 
6.30 ± 
0.60 
13.00 ± 
0.58 
517 ± 
25.0 
52.2 ± 
1.80 
38.40 ± 
0.83 
Devil’s 
claw 
5.65 ± 
0.78 
6.70 ± 
1.10 
13.30 ± 
0.90 
584 ± 
86.5 
52.3 ± 
1.20 
38.50 ± 
2.61 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 2.31: Hematological studies on female mice after chronic treatment (5.4 
mg/kg) with Devil’s claw. 
Hematological indices (Mean ± S. E.) Treatment 
Group WBC x 
109/L 
RBC x 
1012/L 
Hemoglobin
g/dL 
Platelets 
109/L 
MCV 
fL 
HCT 
% ratio 
Control 5.41 ± 0.40 
6.9 ± 
0.4 
13.0 ± 
0.20 
535 ± 
50.0 
51.6 ± 
0.7 
38.8 ± 
2.1 
Devil’s 
claw 
5.20 ± 
0.70 
7.0 ± 
0.2 
13.2 ± 
0.65 
585 ± 
87.0 
52.3 ± 
2.4 
38.5 ± 
1.35 
P > 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 2.32: Biochemical studies on male mice after chronic treatment (5.4 mg/kg) 
with Devil’s claw. 
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 16.40 ± 2.40 
12.80  ± 
1.90 
96.00 ± 
22.00 
83.00 ± 
13.05 
4.55 ± 
0.50 
5.11 ± 
0.30 
Devil’s 
claw 
18.50 ± 
2.91 
13.09 ± 
1.86 
101.13 ± 
24.00 
84.23 ± 
13.69 
4.69 ± 
0.63 
5.15 ± 
0.35 
P > 0.05 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
 
 
 
Table 2.33: Biochemical studies on female mice after chronic treatment (5.4 mg/kg) 
with Devil’s claw. 
Biochemical indices (Mean ± S. E.) Treatment 
Group AST 
(u/l) 
ALT 
(u/l) 
CK-MB 
(u/l) 
Creat. 
(µmole/l) 
Urea 
(mmole/l) 
Glucose 
(mmole/l) 
Control 15.50 ± 6.66 
12.30  ± 
1.63 
98.50 ± 
9.61 
135.61 ± 
2.25 
4.26 ± 
0.35 
5.40 ± 
0.14 
Devil’s 
claw 
16.37 ± 
5.93 
14.73 ± 
2.96 
93.14 ± 
8.39 
130.18 ± 
4.39 
4.20 ± 
0.37 
5.43 ± 
0.16 
P > 0.05 (Student’s t-test). 
Five female mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Table 2.34: Effects of chronic treatment (5.4 mg/kg) with Devil’s claw on the 
femoral cells in mice.  
Treatment 
Group 
Polychromatic 
Erythrocytes 
(PCE) 
Screened 
Micronucleated 
Polychromatic 
Erythrocytes(%)
Normochromatic 
Erythrocytes 
(NCE) Screened 
PCE / NCE 
Ratio 
Control 5200 0.23 ± 0.03 5060 1.04 ± 0.07 
Adriamycin 5000 5.32 ± 0.33** 7596 0.67 ± 0.04* 
Devil’s claw 5148 0.26 ± 0.04 5546 0.93 ± 0.07 
*P < 0.05, **P <0.01 (Student’s t-test). 
Five male mice were used in each group. 
Treatment group was statistically compared with the control group. 
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Liver        Lung 
 
Microphotograph 2.1: A section through the Heart, Kidney, Liver and Lung of mice 
after chronic treatment with Devil's claw capsules showing normal appearance 
(Hematoxyline and eosin X 400).  
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Liver        Lung 
 
Microphotograph 2.2: A section through the Heart, Kidney, Liver and Lung of mice 
after control chronic treatment showing normal appearance  
(Hematoxyline and eosin X 400). 
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3.2.7  Discussion 
 
 
        Devil’s claw is known to possess Iridoid glycosides, including harpagide, 
harpagoside and procumbide; flavonoids, mainly kaempferol and luteolin glycosides; 
phenolic acids; chlorogenic and cinnamic acid; harpagoquinone; triterpenes, sterols, 
oleanolic and ursolic acid derivatives, esters, bitter principles, gum resin, and sugars 
(Leung and Foster 1986; Mabey 1988; Chrubasik 1997). The slight increase observed 
in the liver enzymes in the female mice treatment groups as compared to the control 
during current study, may be attributed to the anti-inflammatory principles of Devil’s 
claw. 
        Histopathology results demonstrated all vital organs of treated mice in different 
groups to be normal and comparable to the control. During current study 
hematological indices showed no significant differences in the treated male and 
female animals as compared to the control. The anti-inflammatory properties of 
Devil’s claw were attributed to harpagoside and β-sitosterol. However, Devil’s claw 
does not appear to inhibit prostaglandin synthesis like most non-steroidal anti-
inflammatory drugs (Moussard et al. 1992; Whitehouse 1983; Andersen et al. 2004). 
Earlier reports on Devil’s claw suggested this natural drug to be as potent as cortisone 
and pheylbutazone, with regards to its anti-inflammatory properties (Ody 1993; 
Mabey 1988; Chrubasik 1997). 
        The effects of H. procumbens (Devil's Claw) found strong evidence that daily 
doses standardized to 50 mg or 100 mg harpagoside were better in short-term 
improvements in pain and rescue medication (Gagnier et al. 2007). The current 
literature review revealed a major safety concern about potential herb-drug 
interactions. This issue is especially important with respect to drugs with narrow 
therapeutic indexes, such as warfarin. Devil’s claw was listed among the herbal drugs 
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which could potentially increase the risk of bleeding or potentiate the effects of 
warfarin therapy (Heck et al. 2000). Patients taking anticoagulants along with Devil’s 
claw are at high risk (Izzo et al. 2005). Devil's claw and many other medicinal plants, 
reinforce warfarin action by heterogeneous mechanisms. Therefore, such herbal drugs 
should not be used in patients on oral anticoagulant and/or antiplatelet therapy 
(Argento et al. 2000). 
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4.   Conclusion 
4.1  For Cat's claw 
        Based on the reports available in the scientific literature it is concluded that the 
root, bark and leaves of Cat’s claw (Uncaria tomentosa (Wild). D.C.) are used 
medicinally in different countries. This plant is officially recognized by the World 
Health Organization as a medicinal plant and it is commonly used as antimicrobial, 
antimutagenic, antioxidant, anti-inflammatory, antitumorous, antiviral, cytostatic, 
diuretic, hypotensive, and immunostimulant.  
        Earlier it was confirmed that two chemo types of Uncaria tomentosa with 
different alkaloid patterns occur in nature. The roots of one type contains pentacyclic 
oxindoles and other contains tetra-cyclic oxindoles which differ in their activities. It 
was proved that tetracyclic oxindole alkaloids dependently reduces the activity of 
pentacyclic oxindole alkaloids on human endothelial cells. (Wurm et al. 1998, 
Kiplinger et al. 1999). 
        Furthermore, tetracyclic oxindole alkaloids act on central nervous system while 
pentacyclic oxindole alkaloids affect the cellular immune system. The mixture of 
these two types of drugs was considered unsuitable for medicinal uses (Hitzman et al. 
2005; Reinhard 1999). 
        During the present study the presence of pentacyclic oxindole alkaloid 
isomitraphylline was confirmed in Cat’s claw capsules by HPLC method. Thus 
confirming the presence of desired compounds in Cat’s claw capsules under 
investigation. 
        To evaluate the stability of Cat’s claw capsules the drug was tested under 
different storage conditions.  The drug was found to be stable under the following 
storage conditions: 25°C / 75% RH, 30°C / 75% RH, 35°C / 75% RH. However, 
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physical examination on the Cat’s claw powder and shell over the period of 24 
months showed that under CH3 storage condition (after 24 months) the capsule 
contents became dark brown while under CH2 and CH3 storage conditions (after 24 
months) the capsule contents became like hard cylindrical lumps. These physical 
changes observed during the present experiments demonstrated that Cat’s claw 
capsules should be stored under the recommended storage conditions.  
         On the other hand, the current stability results do not support the Ministry of 
Health rule of only two years shelf life for all herbal drug products in Saudi Arabia. 
To overcome this rule it is suggested that drug manufacturers submit sufficient 
stability and toxicity data to the Ministry of Health, Saudi Arabia at the time of drug 
registration.  
         Current studies on the elemental composition of Cat’s claw capsules showed the 
presence of traces of sodium and relatively large amount of magnesium, potassium 
and calcium. No toxic heavy metals were found in Cat’s claw capsule contents. 
        Microbiological studies on Cat’s claw capsules revealed no significant changes 
in total viable aerobic count of bacteria and fungi. The total count of viable aerobic 
bacteria and fungi was less than 10 cfu, regardless of storage conditions; thus 
confirming the microbiological stability of this drug product. 
        To evaluate the toxicity of Cat’s claw in mice, short term and long term 
treatment was given and the treatment groups were compared with the animals in the 
control groups. Hematological studies on the male treatment group showed a 
significant reduction in WBC levels and increase in the platelet count of treated male 
mice. No appreciable changes were observed in hematological indices of the treated 
female mice as compared to the control. On the other hand, biochemical studies 
showed statistically significant increase in urea, AST and ALT levels of Cat’s claw 
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treated male and female mice as compared to the control. Histopathological 
investigations confirmed all the vital organs studied to be normal and comparable to 
the control. To confirm the significant differences observed in some parameters 
during the current acute toxicity studies, it was considered essential to conduct sub-
acute toxicity experiment.  
        Contrary to the results of our acute and sub-acute toxicity studies, the WBC 
counts in chronically treated animals were found in the normal range and comparable 
to the control. This shift may be attributed to the appropriate dose used during the 
present chronic toxicity experiment and to the oxindole alkaloids of Cat’s claw which 
were earlier proved to produce a lymphocyte-proliferation-regulating factor which 
normalizes the lymphocyte count without altering the total leukocyte numbers.   
Furthermore, chronic treatment with Cat’s claw induced no clastogenic or cytotoxic 
effects. Based on the results of current study it is concluded that Cat’s claw capsules 
are devoid of any drastic side effects when used according to the suggested dose. 
Moreover, our results will be helpful in planning pre-clinical studies on this herbal 
drug as well. 
         It was concluded that Cat’s claw possessed relatively low toxicity when used 
according to the recommended dose (10 mg/kg/day). However, due to its 
pharmacological activities, Cat’s claw was recommended to be used with caution 
while using other drugs such as: lovastatin (Mevacor), ketoconazole (Nizoral), 
itraconazole (Sporanox), fexofenadine (Allegra) and triazolam (Halicion). 
Furthermore, studies on possible herb-drug interaction should always be reported 
(Saw et al. 2006; Dergal et al. 2002; Santa Maria et al. 1997; Krallendorn 1995; 
Steinberg 1995).  
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4.2  For Devil's claw 
         Based on literature review conducted during the present study, it was concluded 
that Devil’s claw (Harpagophytum procumbens D. C.) is a plant native to south and 
southwestern Africa, Kalahari deserts, Namibia and island of Madagascar where the 
tuber of this plant is used as a remedy for gall, liver, kidney, digestive problems and 
bladder problems. Western herbalists use it in the treatment of rheumatic pain and 
joint problems, mainly arthritis and lumbago. It is also used as lymphatic system 
stimulant to help detoxify the body. The analgesic properties of Devil’s claw can be 
compared in strength to cortisone or phenylbutazone. Various chemical constituents 
including: Iridoid glycosides, acetylphenolic glycosides, flavonoids, phenolic acids, 
harpagoquinone, terpenes, esters, sterols, oleanolic and ursolic acid derivatives were 
isolated from Devil’s claw. Harpagoside, harpagide, procumbide and β-sitosterol 
isolated from the tuber of Devil’s claw were considered as major active compounds 
responsible for the anti-inflammatory and analgesic properties of this plant.  
        The active principle of Devil’s claw called ‘harpagoside’ is used as a marker to 
standardize the drug products. Due to considerable variation in the concentration of 
active constituents of Devil’s claw, the quality control studies on all the finished 
herbal drug formulations containing this plant were highly recommended.  
        Physical examination of Devil’s claw powder revealed that it retained its beige 
color over a period of 24 months of storage under different conditions. The capsule 
shell remained transparent and colorless over the same period. However, under CH2 
and CH3 storage conditions after 24 months, Devil’s claw capsule contents became 
dark brown in color and attained the shape of cylindrical lump. Based on these 
findings it is recommended to adhere to the proper storage conditions specified for 
this drug product. 
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         In the present study, assay of harpagoside and Devil’s claw capsules was done at 
different intervals and conditions according to the validated HPLC method. During 
stability studies, harpagoside in Devil’s claw capsules was found to undergo slight 
decomposition upon storage for six months over the range:  25ºC, 30ºC and 35ºC with 
75% humidity. However, the rate of decomposition increased with the passage of time 
and increase in temperature. 
        The results of elemental analysis done during the present study on Devil’s claw 
capsule contents revealed the presence of potassium, magnesium, calcium and 
sodium. Moreover, the Devil’s claw preparations under study were found to be devoid 
of toxic heavy metals. 
        The results of the current microbiological studies on Devil’s claw revealed no 
significant changes in total viable aerobic count of bacteria and fungi. The total count 
of viable aerobic bacteria and fungi was less than 10 cfu, regardless of storage 
conditions. No primary pathogens such as: Escherichia coli, Staphylococcus aureus, 
Pseudomonas aeruginosa and Salmonella, were found in all the tested samples of 
Devils claw capsules. These results clearly demonstrated the microbiological stability 
of Devils claw capsules under the specified conditions. 
         To evaluate the safety of Devil’s claw acute, sub-acute and chronic toxicity 
studies were carried out on Swiss Albino mice. During acute, sub-acute and chronic 
toxicity experiments Devil’s claw treated animals exhibited no alarming signs of 
toxicity and none of the animals died during the observation period. The body weight 
changes in the treatment groups were comparable to the control. At the end of 
treatment the weight of the vital organs and condition of viscera were normal and 
comparable to the control. Histopathological studies revealed all the animals to be 
normal and comparable to the control. Hematological and biochemical studies showed 
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no significant differences among the animals in the treatment groups and control 
groups. Devil’s claw acute treatment showed no cytotoxic or clastogenic effects in the 
femoral cells of mice. These results clearly demonstrated that Devil’s claw acute 
treatment is devoid of any toxicity 
         Based on the results of current acute, sub-acute and chronic toxicity studies 
Devil’s claw treatment was found to have relatively low toxicity in the given doses. 
However, during earlier experiments Devil’s claw treatment showed the potential to 
stimulate uterine muscles and therefore, should not be used during pregnancy. Such 
properties were attributed to the glycosides and the bitter principles present in Devil’s 
claw. The data obtained during current toxicity studies may provide basic support in 
planning pre-clinical experiments on this plant. 
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4.3   Recommendations 
1-Due to the growing popularity of herbal medicine and as they were sold in many 
countries with medicinal claims or as food supplements ,unfortunately ,side effects 
have been found and there is evidence of serious damage to health, regulations 
covering herbal medicines should be made to ensure the quality, safety, and efficacy. 
 
2-Two chemo types of Uncaria tomentosa (Cat’s claw) with different alkaloid pattern 
occur in nature where one type contains pentacyclic oxindoles and the other contains 
tetra cyclic oxindole alkaloids with completely different pharmacological activities. 
Mixture of these two types of drugs is reported unsuitable for medicinal uses.  It is 
highly recommended to include a limit test for tetracyclic oxindole alkaloid,when 
registering any product containing Cat's claw, to insure its absence. 
 
3-The active principle of Devil’s claw called ‘harpagoside’ is used as a marker to 
standardize the drug products. Due to considerable variation in the concentration of 
active constituents of Devil’s claw, the quality control studies on all the finished 
herbal drug formulations containing this plant were highly recommended. 
  
4-This study provides a valuable preliminary data on the toxicity profile of Cat’s claw 
and Devil's claw that should be useful for the planning of future pre-clinical and 
clinical studies on these herbal drugs. Cat’s claw and Devil's claw appear to be 
relatively non-toxic. However, detailed teratogenic studies are needed to complete the 
safety profile of both drugs. 
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